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Executive summary 
Overview 
Patients requiring specialised care are usually treated by specialist teams with particular expertise 
and equipment.  Concentrating services in this way should be cost-effective but there is concern that 
national tariffs might fail to fully reflect the true costs associated with treating patients that require 
specialised care.  This is because the Healthcare Resource Groups (HRGs), used to categorise 
patients and on which national tariffs are based, may not perfectly differentiate between patients 
that do and do not receive specialised care.  In this analysis we identify whether or not a patient 
received specialised care and evaluate whether and by how much such patients have higher costs 
than those allocated to the same HRG. 
 
Data and methods 
There are two systems for identifying whether or not a patient received specialised care, the 
Specialised Services National Definition Sets (SSNDS) which have since been superseded by the 
Prescribed Specialised Services (PSS) system.  We employ and compare both systems in our analyses. 
 
Of the 18,754,381 Finished Consultant Episodes (FCEs) in the 2011/12 Hospital Episode Statistics 
(HES), 2,183,702 (11.6%) are identified as having received specialised care according to the SSNDS, 
compared to only 1,611,552 (8.6%) under PSS rules.  There is little overlap between the SSNDS and 
PSS: of all those identified as having received specialised care under the two systems, only 537,324 
(16.5%) are identified under both. 
 
We match HES records to Reference Costs (RC) reported by each NHS hospital.  Our analytical 
sample comprises 12,286,246 spells (14,184,683 FCEs) of which 10% are designated as having 
received specialised care according to the SSNDS system and 5.4% according to the PSS system. 
 
We apply regression models to analyse costs for each individual patient to determine whether the 
receipt of specialised care is associated with higher costs relative to patients allocated to the same 
HRG who did not receive specialised care.  Two broad sets of analyses are conducted, according to 
whether the SSNDS or PSS is used to identify receipt of specialised care. 
 
We conduct various sensitivity analyses, including the use of FCEs rather than spells as the unit of 
observation; restriction of the sample to inliers, those who did not stay beyond their HRG-specific 
length of stay trimpoint; and to those who were not allocated to fully specialised or non-specialised 
HRGs; and to relaxing the identification requirement for specialised care that patients have to be 
treated at eligible providers. 
 
Results 
We report results as the percentage difference in cost between those that received specialise care 
and those that did not for each of the SSNDS or PSS specialised care markers. 
 
For the SSNDS markers, we compare previous results for 2009/10 with those for 2011/12.  As well as 
a different population, there will have been changes over time to clinical, coding and costing practice 
and to the HRG casemix classification. Results for 13 of the 27 of the markers are very similar 
between the two years.  For the remainder, the markers are either now statistically significant (8 of 
27) or the cost differentials have changed substantially (6 of 27).  With the exception of 
Neurosciences, for all of these markers changes in volume appear to be the main reason for the 
change.  
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Fewer patients are identified as having received specialised care under the PSS system than the 
SSNDS.  Of the 69 PSS markers that apply to hospital care, 11 apply to fewer than 300 patients 
nationally.  By and large, the percentage cost differences tend to be larger for the PSS markers than 
for the SSNDS markers.  
 
Most of the PSS markers are positive and significant, implying that patients who received specialised 
care of the type indicated had higher costs than other patients allocated to the same HRG.  The cost 
differential between those that do and do not receive specialised care is more than 10% for 28 PSS 
markers; for 16 of these the difference is more than 25%; and for 7 it is more than 50%.  For some 
PSS markers the financial implications of the cost differences will be small, partly because only small 
volumes of patients received the specialised care in question or because the cost differences are 
small. 
 
Conclusions 
Although the PSS system is identifying fewer patients, the fact that the cost differentials are larger 
suggests that identification of those that receive specialised care is more precise under the PSS than 
the SSNDS. 
 
We suggest that top-up payments be applied only to those PSS markers for which the financial 
implications are likely to prove material.  Materiality might be based on both the expected volume of 
patients to whom they are to apply and on the size of the estimated cost differential.  We 
recommend that the calculation of the differential costs between those who did and did not receive 
specialised care is made using the random effects model that takes account of hospital effects.  
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1. Introduction 
In this paper we assess the costs associated with patients treated in hospital that received 
specialised services. Specialised services are defined as:  
 
those services provided in relatively few hospitals, to catchment populations of more than one 
million people. The number of patients accessing these services is small, and a critical mass of 
patients is needed in each treatment centre in order to achieve the best outcomes and 
maintain the clinical competence of NHS staff. These services tend to be located in specialist 
hospital Trusts in major towns and cities. Concentrating services in this way ensures that 
specialist staff can be more easily recruited and their training maintained. It is also more cost-
effective and makes the best use of resources such as high tech equipment and staff expertise. 
http://www.england.nhs.uk/wp-content/uploads/2012/12/pss-manual.pdf   
 
Someone may require specialised care if their condition is particularly severe, if they suffer serious 
underlying problems, or to correct complications following a procedure.  By virtue of their condition, 
therefore, patients directed to specialist teams might be more costly to care for than otherwise 
similar patients who do not require specialised care. 
 
This raises potential problems for hospitals providing specialised care because the reimbursement 
they receive may be insufficient to cover the costs incurred. English hospitals are funded under a 
prospective payment system, formerly termed Payment by Results (PbR) but now called the National 
Tariff Payment System. This ůŝŶŬƐ Ă ŚŽƐƉŝƚĂů ?Ɛ ŝŶĐŽŵĞ ƚŽ ƚŚĞ ŶƵŵďĞƌ ĂŶĚ ĐĂƐĞ ŵŝǆ ŽĨ ƉĂƚŝĞŶƚƐ
treated.  Payments are defined in terms of the healthcare resource group (HRG) to which each 
patient is allocated.  But HRGs are imperfect measures of casemix: any categorization will inevitably 
combine patients with below and above average costs.  This may be problematic if some patients 
assigned to the same HRG require more expensive specialised care while others do not. 
 
The current means of dealing with this problem is to make an additional surcharge over and above 
the base HRG tariff (and excess bedday payment) if there is evidence that the receipt of specialised 
care does increase costs relative to other patients in the same payment category. The following 
surcharges (or top-up payments) apply in the payment policy for 2014/15 (Monitor & NHS England, 
2013): 
 
x ŚŝůĚƌĞŶ ?ƐƐƉĞĐŝĂůŝƐĞĚĐĂƌĞ (high 64%; low 44%) 
x Neurosciences (28%) 
x Orthopaedics (24%) 
x Spinal surgery (32%)  
 
The percentage increases were informed by previous analyses that we conducted for the 
ĞƉĂƌƚŵĞŶƚŽĨ,ĞĂůƚŚ ?ƐWďZteam (Daidone and Street, 2011a, Daidone and Street, 2011b, Daidone 
and Street, 2012, Daidone and Street, 2013).   
 
Since that analytical work was conducted, responsibility for price setting has been transferred from 
the Department of Health to Monitor and NHS England. Moreover, the basis for defining specialised 
services has been reviewed. Previously, specialised care was defined using Specialised Services 
National Definition Sets (SSNDS).  These definition sets have since been superseded by Prescribed 
Specialised Services (PSS).  It is, therefore, necessarily to update the previous analyses to determine 
how top-up payments might be constituted under the new definitional arrangements. 
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To do this, we analyse data from the Admitted Patient Care component of the Hospital Episode 
Statistics for 2011/12.  We describe these data in section 2, detailing how we identify patients who 
received specialised services, defined using SSNDS and PSS rules, and how we match HES records to 
Reference Cost (RC) information.  In section 3 we outline our empirical strategy to investigate the 
extent to which variations in cost are explained by whether or not a patient received a specialised 
service.  We conduct various sensitivity analyses and the basis for each of these in also explained.  
Section 4 provides some summary descriptive statistics.  Section 5 focuses on the results, first for the 
SSNDS markers, then for PSS markers.  Conclusions appear in section 6. 
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2. Data 
We analyse data from the Admitted Patient Care component of the Hospital Episode Statistics for 
2011/12 matched to Reference Cost data for the same year.  There are various issues regarding the 
data that need to be addressed: 
 
x Cleaning HES data 
x How to determine whether or not a patient received specialised care; 
x How to assign costs to each patient record, defined as a Finished Consultant Episode 
(FCE) in the Hospital Episode Statistics; 
x How to determine the cost of a provider spell for those patients who have multiple FCEs; 
 
In Table 1 we summarise how the original HES dataset is reduced to our analytical sample, and the 
number of patients defined as having received some form of specialised care for various sub-
samples of the data. The remainder of this section explains the various steps involved. 
 
Table 1 Starting and analytical samples  
 
Note: patients that receive multiple types of specialised service are counted only once in the counts of FCEs or spells  
 
Details of the breakdown of SSNDS and PSS specialised services by HRG and by provider are provided 
in the accompanying spreadsheet to this report 
www.york.ac.uk/media/che/documents/CHERP103_descriptive_statistics.xlsx.  The spreadsheet also 
provides details of the number of FCEs in HES and those to which Reference Cost data are matched, 
again by HRG and provider. 
  
FCEs
N %
Raw HES 18,889,329        
Duration errors 36,821                0.2%
Duplications 41,591                0.2%
Drop non-acute trusts 56,536                0.3%
After cleaning 18,754,381        99.3%
FCEs
N % N % N %
Cleaned HES 18,754,381        2,183,702        11.6% 1,611,521        8.6% 1,552,209        8.3%
Private Providers (No cost data) 356,960              15,088              4.2% 1,902                0.5% 1,801                0.5%
Zero Cost HRGs 2,091,458          511,664            24.5% 680,168           32.5% 668,660           32.0%
UZ01Z HRGs 214,274              1,906                0.9% 20,604              9.6% 336                    0.2%
Potential Analytical Set 16,097,908        1,655,644        10.3% 908,908           5.6% 881,415           5.5%
Best Cost Match 14,184,683        1,374,992        9.7% 714,132           5.0% 683,830           4.8%
Partial Cost Match 1,049,808          128,470            12.2% 67,166              6.4% 71,402              6.8%
Unmatched 863,417              152,182            17.6% 127,610           14.8% 126,183           14.6%
Spells
Cleaned HES  16,599,033        2,040,562 12.3% 1,563,641 9.4%
Best Cost Match 12,286,246        1,226,434 10.0% 662,197 5.4%
SSNDS PSS CHE PSS Toolkit
4  CHE Research Paper 103  
2.1 Cleaning the HES data 
From an initial sample of 18,889,329 HES episodes, our analytical sample is reduced to 18,754,381 
episodes after cleaning. 
 
x Patients with duration errors (with missing or implausible start and end dates) are 
dropped. There were 36,821 records of this type
a
. 
x Duplicate records are removed, of which we identified 41,591b. 
x We consider only those patients treated in English NHS acute hospitals. Hence, patients 
treated in mental health, ambulance and primary care trusts (with the exception of the 
Isle of Wight) are excluded. 56,536 are dropped for this reason. 
 
2.2 Identifying whether a patient received specialised care 
Specialised Services National Definition Sets (SSNDS) 
The Specialised Services National Definition Sets (SSNDS) define activity as specialised if it requires a 
planning population of over 1 million people.  Specialised care may also be required if the condition 
is particularly severe, if the patient suffers other serious underlying problems, or to correct 
complications following a procedure.  The official site for the SSNDS is now archived, but the 
descriptions and code sheets are available here: http://www.yhscg.nhs.uk/specialised-
services/specialised-services-national-definition-set-version-3.htm  
 
For seven definition sets, no definitive codes are provided because additional criteria must be 
considered in determining whether specialised care is required (for example see (NHS Specialised 
Services, 2010)), so these definition sets are excluded from the analysis. Thus, we construct 27 
dummy variables indicating which type of SSNDS specialised care has been received.   
 
/ŶĨŽƌŵĂƚŝŽŶ ŝŶ ĞĂĐŚ ƉĂƚŝĞŶƚ ?Ɛ ĨŝƌƐƚ ĚŝĂŐŶŽƐƚŝĐ ĂŶĚall procedural fields is examined to ascertain 
whether or not specialised care was received.  A patient is assigned a specialised care marker if one 
of the ICD10 in the primary diagnosis field or one of the OPCS codes
c
 in any of the procedure fields 
designated in the SSNDS is present in their HES record.  ^ŽŵĞ ĐŽĚĞƐ ĂƌĞ ĚĞƐŝŐŶĂƚĞĚ  “ŵĂǇďĞ
ƐƉĞĐŝĂůŝƐĞĚ ?ĂŶĚǁĞĚŽŶŽƚŝŶĐůƵĚĞƚŚĞƐĞĨŽƌŝĚĞŶƚŝĨŝĐĂƚŝŽŶƉƵƌƉŽƐĞƐ ?  In contrast, for identification 
purposes, the patient has to have been treated at provider deemed eligible for top-up payments, 
because non-eligible providers should not be providing specialised services. 
 
In Table 2 we report the counts of these codes in HES data for 2011/12, the grand total amounting to 
2,277,396.  Note that this is not a count of the number of individuals that have received specialised 
care: individuals may have multiple specialised codes.  There are 93,694 FCEs for which more than 
one specialised service is identified.  In total, therefore, 2,183,702 FCEs are identified as having 
received specialised care as defined by the SSNDS (Table 1).  
 
 
  
                                                     
a
 ƵƌĂƚŝŽŶĞƌƌŽƌƐŝŶĐůƵĚĞƚŚŽƐĞ&ƐǁŝƚŚĞƉŝƐŽĚĞƐƚĂƌƚĂŶĚĞŶĚĚĂƚĞƐŝĚĞŶƚŝĨŝĞĚĂƐĞƌƌŽŶĞŽƵƐǁŝƚŚŝŶ,^ǀŝĂĚĂƚĞ ‘ĐŚĞĐŬ-
ĨůĂŐƐ ?ƉůƵƐƚŚŽƐĞ&ƐǁŚŽƐĞĞŶĚĚĂƚĞŽĐĐƵƌƌĞĚďĞĨŽƌĞƚŚĞƐƚĂƌƚĚĂƚĞ ? 
b
 Duplicates are defined as FCEs having the same patient ID, episode start and end dates, admission start and end dates 
and having the same CHE-defined transition value (no transfer ; transfer out only ; transfer in and out; transfer in only). 
c
 ICD10: International Statistical Classification of Diseases and Related Health Problems 10th Revision; OPCS: Office for 
Population Censuses and Surveys Classification of Surgical Operations and Procedures 
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Table 2 Occurrences of SSNDS markers in HES 2011/12 
 
Note: only the above 27 SSNDS chapters are based entirely on ICD and/or OPCS codes 
 
Prescribed Specialised Services (PSS) 
The Health and Social Care Act 2012 transferred responsibility for commissioning specialised services 
from Primary Care Trusts (PCTs) to the newly established NHS Commissioning Board (NHS CB), since 
renamed NHS England.  As part of the transfer of responsibility, the opportunity was taken to review 
the rules used to determine what constituted specialised care.  This led to a new set of definitions 
being drawn up by which to determine what should constitute Prescribed Specialised Services (PSS), 
which have now replaced the SSNDS (NHS Commissioning Board, 2012) and has been recommended 
to Ministers (Department of Health, 2014)  
 
The general definition of specialised services ƵƐĞĚ ĨŽƌ ^^E^ ƌĞŵĂŝŶĞĚ ? ƚŚŝƐ ďĞŝŶŐ ƚŚĂƚ ƚŚĞǇ  “are 
those services provided in relatively few hospitals, to catchment populations of more than one 
million people ?.  But four factors were explicitly set out for determining whether services should be 
directly commissioned by NHS England instead of by the Clinical Commissioning Groups (CCGs) that 
replaced PCTs: 
 
SSNDS Service 
Number
 SSNDS Label  N 
TOTAL 2,277,396    
1 Specialised cancer services (adult) 24,872          
2 Specialised services for blood and marrow transplantation (all ages) 580                
3 Specialised services for haemophilia and other related bleeding disorders (all ages) 455                
4 ^ƉĞĐŝĂůŝƐĞĚƐĞƌǀŝĐĞƐĨŽƌǁŽŵĞŶ ?ƐŚĞĂůƚŚ ?ĂĚƵůƚ ? 30,536          
5 Assessment and provision of equipment for people with complex physical disability (all ages) -                
6 Specialised spinal services (all ages) 14,787          
7 Specialised rehabilitation services for brain injury and complex disability (adult) -                
8 Specialised neurosciences services (adult) 38,312          
9 Specialised burn care services (all ages) -                
10 Cystic fibrosis services (all ages) 263,439       
11 Specialised renal services (adult) 501,863       
12 Specialised intestinal failure and home parenteral nutrition services (adult) 2,857            
13 Specialised cardiology and cardiac surgery services (adult) 170,948       
15 Cleft lip and palate services (all ages) 270,901       
16 Specialised immunology services (all ages) -                
17 Specialised allergy services (all ages) -                
18 Specialised services for infectious diseases (all ages) 2,253            
19 Specialised services for liver, biliary and pancreatic medicine and surgery (adult) 68,753          
20 Medical genetic services (all ages) -                
22 Specialised mental health services (all ages) -                
23 Specialised services for children 320,262       
24 Specialised dermatology services (all ages) 10,691          
26 Specialised rheumatology services (all ages) 1,478            
27 Specialised endocrinology services (adult) 9,599            
29 Specialised respiratory services (adult) 298,280       
30 Specialised vascular services (adult) 2,852            
31 Specialised pain management services (adult) 1,322            
32 Specialised ear services (all ages) 2,873            
33 Specialised colorectal services (adult) 12,423          
34 Specialised orthopaedic services (adult) 5,593            
35 Specialised morbid obesity services (all ages) 17,962          
36 Specialised services for metabolic disorders (all ages) New for 3rd edition 4,648            
37 Specialised ophthalmology services (adult) New for 3rd edition 8,197            
38 Specialised haemoglobinopathy services (all ages) New for 3rd edition 190,660       
6  CHE Research Paper 103  
1. The number of individuals who require the provision of the service or facility;  
2. The cost of providing the service or facility;  
3. The number of persons able to provide the service or facility; and  
4. The financial implications for CCGs if they were required to arrange for the provision of the 
service or facility 
 
The PSS manual published in 2014 sets out definitions for 143 groups of specialised services, of 
which 69 relate to services for patients admitted to hospital (NHS England, 2014).  
 
The Health & Social Care Information Centre (HSCIC) has made available an Identification Toolkit as a 
software package that allows users to apply nationally consistent rules to identify prescribed 
specialised services in analysing patient-level data.  The Prescribed Services 2013-14 Identification 
Tool (hereafter PSS toolkit), designed to be used alongside the HRG Grouper products for use in the 
2013-14 financial year, is available here:  
http://www.hscic.gov.uk/casemix/prescribedspecialisedservices  
 
The primary purpose of the PSS Toolkit is to support financial arrangements so, as well as including 
rules to identify whether or not the requisite ICD and OPCS codes appear in each HES record, the PSS 
toolkit also includes various checks of the quality of data in other HES fields.  If any of these quality 
checks fail, a record will not be assigned to one of the PSS groups, even if the relevant ICD or OPCS 
codes appear.  These data quality checks are described in the table on page 14 of the manual (Health 
& Social Care Information Centre, 2013)  
 
In addition, for some PSS service lines the patient has to have been treated at an eligible provider for 
identification of the care as specialised.  The PSS toolkit also embodies a set of hierarchical rules 
such that, in the case that someone has multiple PSS codes, the record is assigned to just one of the 
PSS groups. 
 
As the data quality checks are not pertinent for the purposes of the cost analyses that are the 
subject of this report, we have programmed the PSS coding rules ourselves.  This provides the added 
benefit of allowing us to perform sensitivity analyses to how the rules are applied.  Our CHE code is 
programmed in SAS and implements the rules and ICD and OPCS codes as described in this 
spreadsheet-http://www.hscic.gov.uk/media/11878/PS-201314-Identification-Code-
Sets/xls/PS_2013_14_Prescribed_Services_Identification_Code_Sets_v1.1.xlsx. A number of 
technical decisions had to be made in order to apply the PSS rules to the 2011/12 data, and these 
are detailed in appendix A2. 
 
A subset of 69 PSS groups applies to patients that appear in the Hospital Episode Statistics for 
2011/12.  These are listed in Table 3, together with information about the number of counts of each 
PSS marker in HES: 
 
1. The column entitled  “PSS CHE count ? applies our programmed PSS Identification Rules and 
details the number of times that a specialised service is triggered by the identification rules 
for patients treated at eligible providers. Our programme identifies 1,771,892 instances of 
these relevant codes appearing in the data.  Note that individual records may trigger 
multiple specialised codes. 
2. dŚĞ ĚĂƚĂ ŝŶ ĐŽůƵŵŶ ĞŶƚŝƚůĞĚ  “PSS dŽŽůŬŝƚ ĐŽƵŶƚ ? ŝƐ ĚĞƌŝǀĞĚ ĨƌŽŵ ƌƵŶŶŝŶŐ ƚŚĞ ,^ ĚĂƚĂ
through the PSS toolkit.  This means that HES records are only identified as specialised if 
they contain the relevant codes but also satisfy thĞƚŽŽůŬŝƚ ?ƐĚĂƚĂƋƵĂůŝƚǇĐŚĞĐŬƐ and if the 
patient was treated at an eligible provider.  Unsurprisingly, therefore, fewer records are 
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identified as specialised than if these quality checks are not applied.  The total number of 
codes identified by the Toolkit amounts to 1,718,306. 
3. The final column ?ŚĞĂĚĞĚ  “dŽŽůŬŝƚŽŵŝŶĂŶƚŽƵŶƚ ? ? ĂƉƉůŝĞƐ ƚŚĞdŽŽůŬŝƚ ?ƐW^^ŚŝĞƌĂƌĐŚǇƚŽ
assign each record (ie FCE) to a single PSS group.  Because each FCE is assigned to only a 
single PSS group, in essence, this is a count of the number of FCEs in which specialised care 
was delivered, a total of 1,545,701. 
 
There are two sets of service lines in which the PSS CHE counts and PSS Toolkit counts differ, namely 
ŚŝůĚƌĞŶ ?Ɛ ƐĞƌǀŝĐĞƐ ĂŶĚ ,ŝŐŚůǇ ^ƉĞĐŝĂůŝƐĞĚ ƐĞƌǀŝĐĞƐ ?/Ŷ Ăůů ĐĂƐĞƐ ŽƚŚĞƌ ƚŚĂŶ ŚŝůĚƌĞŶ ?Ɛ ^ƵƌŐĞƌǇ
(NCBPS23X  W E03), the PSS CHE counts are higher than those of the PSS Toolkit. Discrepancies were 
reviewed in conjunction with the Technical Working Group for this work, members of which were 
ĚƌĂǁŶ ĨƌŽŵ ƚŚĞ ƉƌŽũĞĐƚ ?Ɛ tŽƌŬŝŶŐ 'ƌŽƵƉ ?listed in Appendix 1. The reasons for the discrepancies 
between the PSS CHE and PSS Toolkit counts are detailed in Appendix 2.  
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Table 3 Occurrences of PSS markers in HES 2011/12 
 
 
PSS Code PSS Description  CHE Count   Toolkit Count 
 Toolkit 
Dominant Count  
TOTAL 1,771,892         1,718,306          1,545,701                
NCBPS01C B03 - Chemotherapy 667,767             656,002              607,274                    
NCBPS01P B02 - PET-CT 757                     668                      468                            
NCBPS01R B01 - Radiotherapy 78,970               76,454                66,123                      
NCBPS01S D05 - Stereotactic Radiosurgery 1,401                 1,334                   1,334                         
NCBPS01T B03 - Teenage and Young Adults Cancer 14,600               14,460                10,019                      
NCBPS01Y B03 - Rare Cancers (Adult) 67,896               66,921                60,051                      
NCBPS02Z B04 - BMT 3,053                 2,957                   2,950                         
NCBPS03Z B05  - Haemophilia 4,591                 3,673                   3,673                         
NCBPS04A E10 - Women - Complex Minimal Access Gynaecology Surgery 1,526                 1,080                   1,080                         
NCBPS04C E12 - Women - Fetal Medicine 182                     180                      179                            
NCBPS04D E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 16                       12                         12                               
NCBPS04E E11 - Women - Maternal Medicine (complications of pregnancy) 45,138               44,021                43,929                      
NCBPS06Z D14 - Spinal - Spinal Surgery 8,174                 7,118                   4,213                         
NCBPS08O D04 - Neurosciences - Neurology 127,996             125,407              125,385                    
NCBPS08P D04 - Neurosciences - Neurophysiology 175                     173                      173                            
NCBPS08R D04 - Neurosciences - Neuroradiology 32                       30                         29                               
NCBPS08S D03 - Neurosciences - Neurosurgery 76,697               67,796                66,808                      
NCBPS09Z D06 - Burns Care 5,923                 5,137                   5,137                         
NCBPS10Z A01 - Cystic fibrosis 12,158               10,989                10,932                      
NCBPS11C A06 - Renal Services - Access for dialysis 16,392               11,297                10,855                      
NCBPS11T A07  - Renal Services - Renal Transplantation 10,681               9,254                   9,253                         
NCBPS13B A09 - Cardiac - Cardiac electrophysiology 6,890                 6,856                   6,854                         
NCBPS13C A09 - Cardiac - Inherited heart disorders 7,330                 7,262                   7,188                         
NCBPS13E A10 - Cardiac - Cardiac surgery 45,269               40,589                39,520                      
NCBPS13F A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 41,432               36,986                35,034                      
NCBPS13G A11 - Cardiac - Pulmonary hypertension 4,443                 4,379                   3,962                         
NCBPS13H A10 - Cardiac - Cardiovascular magnetic resonance 4,560                 4,508                   2,571                         
NCBPS13K A10 - Cardiac - Other 20,440               20,130                18,670                      
NCBPS13X A13 - Adult Congenital Heart Disease 7,407                 7,331                   7,179                         
NCBPS14Z B06 - HIV 7,946                 8                           8                                 
NCBPS15Z D07 - Cleft Lip Palate 2,844                 2,064                   2,064                         
NCBPS16Z B09 - Immunology 10,985               10,938                10,932                      
NCBPS17Z B09 - Allergy 2,538                 2,538                   2,538                         
NCBPS18A B07 - Infectious Diseases Adult 326                     308                      308                            
NCBPS18C B07 - Infectious Diseases Paeds 2,366                 303                      303                            
NCBPS19Z A02 - Hepatology & Pancreatic 4,026                 3,901                   3,879                         
NCBPS22Z C04 - Mental Health - Gender Dysphoria 163                     162                      161                            
NCBPS23A E04 - Childrens services - Cancer 57,279               55,038                38,342                      
NCBPS23B E05 - Childrens services - Cardiac 24,025               23,388                15,649                      
NCBPS23E E03 - Childrens services - Endocrinology 3,936                 3,865                   3,729                         
NCBPS23F E03 - Childrens services - Gastroenterology 84,100               78,101                69,398                      
NCBPS23H E03 - Childrens services - Haematology 2,409                 2,383                   1,677                         
NCBPS23M E09 - Childrens services - Neurosciences 17,407               16,804                12,766                      
NCBPS23N E03 - Childrens services - Ophthalmology 8,091                 7,764                   7,413                         
NCBPS23S E03 - Childrens services - Renal 14,685               8,580                   6,731                         
NCBPS23T E03 - Childrens services - Respiratory 10,163               9,949                   7,974                         
NCBPS23W E03 - Childrens services - Rheumatology 8,600                 7,769                   5,872                         
NCBPS23X E02 - Childrens services - Surgery 65,472               110,942              90,564                      
NCBPS23Y E03 - Childrens services - Paediatric Pain Management 25                       23                         21                               
NCBPS28Z D11 - Hyperbaric Oxygen Treatment 18                       14                         13                               
NCBPS29A A03d - Respiratory - Pulmonary vascular services 275                     270                      128                            
NCBPS29B A12 - Respiratory - Complex thoracic surgery 43,816               42,712                20,261                      
NCBPS29E A03d - Respiratory - Management of central airway obstruction 3,147                 3,052                   2,628                         
NCBPS29M A03d - Respiratory - Interstitial lung disease 3,817                 3,710                   3,605                         
NCBPS29R A03d - Respiratory - Other 25,252               23,636                21,904                      
NCBPS30Z A04 - Vascular Services 7,438                 7,320                   6,287                         
NCBPS32A D09 - Ears - Cochlear Implants 1,251                 1,240                   1,238                         
NCBPS32B D09 - Ears - Bone anchored hearing aids 1,388                 1,376                   1,375                         
NCBPS32D D09 - Ears - Middle Ear Implants 119                     119                      116                            
NCBPS33A A08 - Colorectal - Complex Surgery for Incontinence 1,692                 1,684                   1,684                         
NCBPS33B A08 - Colorectal - Complex Inflammatory Bowel disease 88                       86                         80                               
NCBPS33C A08 - Colorectal - Transanal Endoscopic Microsurgery 535                     533                      533                            
NCBPS34A D10 - Orthopaedic Surgery 2,007                 1,953                   1,939                         
NCBPS34R D10 - Orthopaedic Surgery - revisions 188                     133                      133                            
NCBPS35Z A05 - Morbid Obesity Surgery 9,170                 9,117                   9,116                         
NCBPS37Z D12 - Ophthalmology 20,850               20,755                20,731                      
NCBPS38S B08 - Haemoglobinopathy - Sickle Cell 14,101               13,925                13,907                      
NCBPS38T B08 - Haemoglobinopathy - Thalassaemia 8,873                 8,839                   8,839                         
NCBPS99Z Highly Specialised 18,585               -                       -                             
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In the analysis that follows we apply our CHE coding rules to identify whether or not a patient 
received specialised care as defined by the PSS. As well as the data quality checks not being 
necessary for the analysis, this allows us to relax the conditions regarding provider eligibility and the 
hierarchy of the PSS markers. 
 
Comparison of SSNDS and PSS 
Although it was intended that the PSS would not be a radical departure from SSNDS, it turns out that 
the definition sets differ considerably in terms of whether or not somebody is identified as having 
received specialised care during their time in hospital.  For the 18,754,381 FCEs in HES in 2011/12, 
the SSNDS identifies 2,183,702 as involving specialised care while the PSS identifies only 1,611,521 
(Table 4).  
 
The (lack of) overlap between the two means of defining specialised services is also shown.  Only 
16.5% of these HES records are common across the SSNDS and PSS identification systems.  By 
implication, SSNDS and PSS appear to be markedly different systems.  Consequently, replacing the 
SSNDS by the PSS is expected to lead to substantial changes in which particular patients are 
identified as having received specialised care and, therefore, in estimates of the additional costs 
associated with receipt of this care. 
 
Table 4 Classification of HES records under SSNDS and PSS definitions 
SSNDS only Overlap PSS Only 
1,646,378 537,324 1,074,197 
50.53% 16.49% 32.97% 
   
   Total SSNDS:            2,183,702  
 Total PSS:            1,611,521  
  
2.3 Mapping of reference costs to HES records 
Some HES records are dropped from the analysis because cost information is unavailable. For the 
remainder, wĞŵĂƉĞĂĐŚƉĂƚŝĞŶƚ ?Ɛ,^ƌĞĐŽƌĚƚŽZĞĨĞƌĞŶĐĞŽƐƚĚĂƚĂƌĞƉŽƌƚĞĚďǇĂůůE,^ŚŽƐƉŝƚĂůƐ ?
For each HES record (FCE), there are three main elements that require costing: 
 
1. dŚĞƉĂƚŝĞŶƚ ?ƐbaseHRG; 
2. dŚĞĐŽƐƚŽĨĞǆĐĞƐƐďĞĚĚĂǇƐďĞǇŽŶĚƚŚĞƉĂƚŝĞŶƚ ?Ɛ,Z'ƐƉĞĐŝĨŝĐůĞŶŐƚŚŽĨƐƚĂǇƚƌŝŵƉŽŝŶƚ ? 
3. Any so-ĐĂůůĞĚ “ƵŶďƵŶĚůĞĚ ?,Z'ƐƚŽǁŚŝĐŚƚŚĞƉĂƚŝĞŶƚŝƐĂƐƐŝŐŶĞĚ. 
 
Private providers, HRG UZ01Z and zero cost HRGs 
Private providers do not report cost information, so NHS patients treated at private providers 
(n=356,960) are dropped from further analysis.  For information, Table 1 reports the proportion of 
NHS patients treated at private providers identified as having received specialised care. 
 
Patients without the requisite information in their HES record to determine HRG allocation are 
assigned to the unallocated HRG UZ01Z.  There are 214,274 (1.1%) HES records of this nature, and 
these are excluded from further analysis.  
 
There is a significant difference in the number of UZ01Z HRGs assigned to PSS CHE specialised 
services compared to those identified by the PSS toolkit.  The reason for this is that some data items  
that trigger a UZ01Z HRG are included in the PSS toolkit quality check but not in the PSS CHE version.  
For example, there is missing provider spell number in almost all HIV cases, which means that the 
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PSS toolkit only identifies 8 cases whereas the PSS CHE version identifies 7,946 cases.  When the 
grouper is used to assign an HRG to the FCE, the missing provider spell number (and other grouper 
data quality check) assigns a UZ01Z to all of these FCEs. 
 
Some HRGs have a zero cost attached to them, in accordance with the Reference Cost requirements.  
Table 5 below lists these HRGs and the number of FCEs associated with them.  As these patients 
attract a zero cost, these are excluded from the analysis.  There is a total of 2,091,458 (11.2%) such 
cases. 
 
Table 5 HRGs attracting a zero Reference Cost 
HRG 
  
 FCEs  
  
      
TOTAL 
 
2,091,458 
   
   
DZ13A Cystic Fibrosis with CC 6,651 
DZ13B Cystic Fibrosis without CC 1,049 
LA08E 
Chronic Kidney Disease with length of stay 1 day or less, associated with Renal 
Dialysis 
916,952 
PA13C Cystic Fibrosis with length of stay 0 days 2,681 
PA13D Cystic Fibrosis with length of stay between 1 and 7 days 1,577 
PA13E Cystic Fibrosis with length of stay between 8 and 14 days 1,546 
PA13F Cystic Fibrosis with length of stay 15 days or more 500 
PB03Z Healthy Baby 486,728 
SB97Z Same Day Chemotherapy Admission or Attendance 612,416 
SC97Z Same Day External Beam Radiotherapy Admission or Attendance 61,358 
 
The PSS CHE tool identifies approximately 12,000 FCEs which trigger the Cystic Fibrosis (CF) 
specialised service.  Of those cases, approximately 90% are grouped to a zero-cost HRG and thus do 
not appear in the analytical sample.  The remaining 10% of cases have data which trigger different 
HRGs and are probably not a representative sample of CF specialised services. As such, caution 
should be attached to any interpretation of the estimated CF parameter. 
 
The cost of the base HRG and excess bed days 
We match ĞĂĐŚŚŽƐƉŝƚĂů ?ƐRC data to its patients HES records in order to establish the cost of the 
base HRG to which they are allocated.  For elective and non-elective cases, when the length of stay 
ŐŽĞƐďĞǇŽŶĚ,Z'ƐƉĞĐŝĨŝĐƚƌŝŵƉŽŝŶƚƐ ?ǁĞĂĚĚƚŚĞŚŽƐƉŝƚĂů ?ƐĞǆĐĞƐƐper diem cost for each additional 
day.  There are 4.1% of FCEs for which length of stay exceeds their HRG trimporint.  
 
For the majority of HES records, a  “Best ? matching is possible.  For others, matching can be achieved 
by relaxing some of the matching criteria.  
 
1. RC_ID.   “Best ?match of RC and HES data is achieved if it is possible to identify the 
reference cost for the episode through a combination of the Trust code, Department 
Code (e.g. NEI_L), Service Code (e.g. 300) and HRG code (e.g. EB07H). On this basis, it is 
possible to match 90% of FCEs to a base HRG cost and 72% to the excess bed day costs. 
  
/Ĩ ĂŶ & ĐĂŶŶŽƚ ďĞ ŵĂƚĐŚĞĚ ƵŶĚĞƌ ƚŚĞƐĞ ĐƌŝƚĞƌŝĂ ?  “Partial ? ŵĂƚĐŚŝŶŐ ŝƐ ĂĐŚŝĞǀĞĚ ďǇ ƌĞůĂǆŝŶŐ
conditions successively: 
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2. DC_ID: This identifies the reference cost through a combination of Trust, Department 
Code and HRG (i.e. does not use Service Code for matching).  Dropping the service code 
allows matching of an additional 4.5% of FCEs to a base HRG cost.  
  
3. SC_ID: This identifies the reference cost through a combination of Trust, Service Code 
and HRG (i.e. does not use Department Code for matching).  Dropping the service code 
allows matching of an additional 1.7% of FCEs to a base HRG cost. 
  
4. HRG_ID: This identifies the reference cost through a combination of only Trust and HRG. 
Relaxing this final condition allows an additional 0.3% of FCEs to a base HRG cost. 
 
We define two analytical samples.  dŚĞĨŝƌƐƚŝŶĐůƵĚĞƐŽŶůǇƚŚŽƐĞ&ƐŝŶǁŚŝĐŚ “ƉĞƌĨĞĐƚ ?ŵĂƚĐŚŝŶŐŽĨ
FCEs to RC has been achieved.  dŚŝƐĨŽƌŵƐŽƵƌ “ďĂƐĞůŝŶĞ ?ĂŶalytical sample, and comprises a total of 
14,184,683 FCEs (Table 6).  
 
The second includes the partial matches defined through steps 2-4.  This process assigns costs to an 
additional 1,049,808 (6.9%) HRGs.  This provides a greater analytical sample of 15,234,491 FCEs, 
which is used as a sensitivity analysis.  We do not include partial matches in the baseline analysis 
because, by supposition, the quality of their cost data is poorer. 
 
Table 6 Matching of HES records to Reference Cost information 
  
Core HRG 
 
Excess bed 
day 
 
All FCEs  
RC_ID "Best" match 14,804,031  93.3% 473,286  78.4% 14,184,683 93.1% 
DC_ID + 
SC_ID + 
HRG_ID 
 “Partial ?ŵĂƚĐŚ 1,067,329  6.7% 130,013  21.6% 1,049,808 6.9% 
 
Total with costs 15,871,360  
 
603,299   15,234,491  
 
 
Unbundled HRGs 
Around 1.9m FCEs have unbundled activities associated with them. For 73% of these FCEs we can 
attach a cost to each of the constituent unbundled HRGs. For 690k FCEs there are missing costs for 
at least one unbundled activity. These cases are excluded from the regression analyses. 
 
Assessing the cost of provider spells 
To be able to determine the number of individuals that received specialised care we need to convert 
ƚŚĞ ,^ ĚĂƚĂ ŝŶƚŽ  “ƉƌŽǀŝĚĞƌ ƐƉĞůůƐ ? ?  Each observation in HES comprises a Finished Consultant 
Episode (FCE), measuring the time the patient spends under the care of a particular consultant.  
Around 90% of patients remain under the care of a single consultant during their entire hospital 
stay.  The remainder are cared for by more than one consultant, most usually because they are 
transferred from one specialty to another.  We track the consultant episodes pertaining to each 
individual patient, allowing us to construct a provider spell for each patient, measuring the time 
from admission to discharge.  
 
Multi-episode spells are likely to be more costly than single-episode spells, but there is no agreed 
method for determining the additional cost.  In our previous work we found that estimation results 
were not sensitive to whether the cost of multi-episode spells was based on the Sum, Maximum or 
First of the costs of the constituent FCEs.  Consequently, in the analysis that follows, the cost of a 
provider sƉĞůů ŝƐ ĐĂůĐƵůĂƚĞĚ ĂƐ ƚŚĞ ^Ƶŵ ŽĨ ƚŚĞ ĐŽƐƚ ŽĨ ĞĂĐŚ & ĐŽŵƉƌŝƐŝŶŐ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƐƉĞůů ŝŶ
hospital. 
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For this analysis we define tŚĞ ƉĂƚŝĞŶƚ ?Ɛbase HRG as that which proves most costly among the 
alternatives to which the patient is assigned across the constituent FCEs.  After re-restructuring the 
HES data so that it comprises observations defined as patient spells, we have an analytical sample of 
12,293,231 spells. 10% of these patients received specialised care as defined by the SSNDS, 5.4% as 
defined by the PSS (Table 1). 
 
We are now in a position to turn to the question of whether the cost of the care for these patients 
differs to that for other patients assigned to the same HRG.  
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3. Estimation models 
3.1 Dependent variable 
In our analyses, all costs reported by hospitals are adjusted by the market forces factor (MFF), this 
being an index of geographical variation in the prices of land, buildings, and labour, designed to 
account for unavoidable differences in factor prices incurred by different hospitals. 
 
The dependent variable is defined as ƚŚĞƉĂƚŝĞŶƚ ?ƐƐƚĂŶĚĂƌĚŝƐĞĚĐŽƐƚݕ௜௞ ൌ ܿ௜௛௞ Ƹܿ௛ൗ   where ܿ௜௛௞ is the 
cost of patient i in HRG4 h in hospital k and  Ƹܿ௛ is the national average cost of all patients allocated to 
ƚŚĞƉĂƚŝĞŶƚ ?Ɛbase HRG4 h. The main reason for defining the dependent variable in this way is that, 
with some mathematical manipulation, we can calculate the percentage difference associated with 
receipt of specialised care.  
 
Ideally, we would have patient-level costs, constructed using detailed information about all the 
resources used to provide treatment to each individual patient. If such information were available, 
the cost distribution for patients in a particular HRG might appear similar to that illustrated in panel 
[a] of Figure 1. 
 
[a] [b] 
 
 
[c] 
 
Figure 1 Illustration of the distribution of costs within a HRG 
 
But the Reference Cost data collected in England are not based on precise information about patient 
ƌĞƐŽƵƌĐĞ ƵƐĞ ? ZĂƚŚĞƌ ? ƚŚĞ  “ďŽƚƚŽŵ-ĚŽǁŶ ? ĐŽƐƚŝŶŐ ƉƌŽĐĞƐƐĞƐ ŵĞĂŶ ƚŚĂƚ ƐŽŵĞpatients might be 
assigned the same costs, namely those treated in the same hospital, with same Department Code 
(e.g. NEI_L , indicating admission method), the same Service Code (e.g. 300, indicating treatment 
specialty), and the same HRG code (e.g. EB07H). This will affect those discharged prior to the HRG-
specific trimpoint, the associated cost of which is indicated in panel [b] as vertical red line. The cost 
distribution for patients discharged prior to the trimpoint can be illustrated as a set of bars, in which 
patients are grouped to the same cost value. For patients discharged beyond the trimpoint, costs 
reflect excess bed days, so the distribution for these patients will appear as a continuous set of 
values.  
pa
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The analytical task is to determine whether patients that received specialised care are more likely to 
appear toward the higher end of the cost distribution than those who do not. If such patients are 
more costly, the distribution might be similar to that illustrated in panel [c]. Costs for patients that 
received specialised services are indicated in red; those that did not are indicated in yellow.  
 
If provision of specialised care is more costly:  
 
x For inlier patients, those that received specialised care will appear closer to trimpoint than 
other patients allocated to the same HRG.  
x For outlier patients, those that received specialised care will be less likely to have costs 
closer to trimpoint. This possibility is illustrated by the different height and length of the 
distributions of costs for those that did and did not receive specialised care.   
 
KƵƌ ĂŶĂůǇƚŝĐĂů ŵŽĚĞůƐ ĂƌĞ ĚĞƐŝŐŶĞĚ ƚŽ ĚĞƚĞƌŵŝŶĞ ǁŚĞƚŚĞƌ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ ůŽĐĂƚŝŽŶ ŝŶ ƚŚĞ ĐŽƐƚ
distribution is related to whether and what type of specialised care they received. 
 
3.2 Additional costs of SSNDS defined specialised care 
If no account is taken of the possibility that costs may be partly related to the hospital in which care 
is provided, the additional costs associated with receipt of specialised care are estimated by 
regresƐŝŶŐ ĞĂĐŚ ƉĂƚŝĞŶƚ ?Ɛ ƐƚĂŶĚĂƌĚŝƐĞĚ ĐŽƐƚ ĂŐĂŝŶƐƚ ƚŚĞset (nA? ? ?N) of SSNDS specialised care 
markers (S) indicating the type of specialised care received (if any). So, for any individual i, ܵ௡௜ ൌ  ? if 
the patient received specialised care of type n, and 0 otherwise.  The model takes the form: 
 ݕ௜ ൌן ൅  ? ߚ௡ܵ௡௜ ൅ ߝ௜ே௡ୀଵ         (EQ1) 
 
where ߚ are the parameters to be estimated: if positive and significant, a patient with the specialist 
care marker has higher costs than do other patients allocated to the same HRG. ߝ௜  captures random 
error.  The model is estimated using ordinary least squares (OLS). 
 
This model fails to recognise that costs may be driven partly by the hospital in which the patient is 
treated. This can be examined by specifying a hierarchical model of the form: 
 ݕ௜௞ ൌן ൅  ? ߚ௡ܵ௡௜௞ ൅ ݑ௞ ൅ ݒ௜௞ே௡ୀଵ        (EQ2) 
 
This is a multi-level model that recognises that patients (iA? ? ?I) are clustered within hospitals 
(kA? ? ?K). ݑ௞ is the hospital random effect: patients treated in hospitals with higher effects have 
higher costs than those treated elsewhere, over and above the costs estimated to be due to delivery 
of specialised services.   ݒ௜௞ captures random measurement error.  We argue that this is the 
preferred model on which top-up payments should be made as it identifies the additional costs 
associated with receipt of specialised care, after controlling for the influence on costs of the hospital 
where treatment was provided. 
 
In order to derive the percentage increase in costs associated with receipt of specialised care, ݃௡, we 
compute the marginal mean for both specialised and non-specialised services: 
 ݃௡ ൌ ாሺ௬೔ȁௌ೙ୀଵǡࡿሻିாሺ௬೔ȁௌ೙ୀ଴ǡࡿሻாሺ௬೔ȁௌ೙ୀ଴ǡࡿሻ כ  ? ? ?       (EQ3) 
 
3.3 Additional costs of PSS defined specialised care 
As detailed earlier, a new means of defining specialised services has been developed, the so-called 
Prescribed Specialised Services (PSS).  In order to evaluate the additional costs associated with these 
The costs of specialised care  15 
 
 
newly defined markers, the estimation models are similar to those specified above, with the 
exception that the SSNDS specialist markers are replaced by the set of PSS definitions. So EQ1 can be 
written as: 
 ݕ௜ ൌן ൅  ? ߚ௣ ௣ܲ௜ ൅ ߝ௜௉௣ୀଵ         (EQ4) 
 
Here the PSS definition sets (pA? ? ?P) comprises the specialised care markers (R) indicating the newly 
defined type of specialised care received (if any). Similarly, the multi-level model specified in EQ2 
becomes: 
 ݕ௜௞ ൌן ൅  ? ߚ௣ܴ௣௜௞ ൅ ݑ௞ ൅ ݒ௜௞௉௣ୀଵ        (EQ5) 
 
3.4 Sensitivity analyses 
We consider the sensitivity of estimates derived from applying equation 1 to: 
 
x FCEs: using FCEs rather than spells as the unit of analysis. 
x Inliers: restricting analysis to those patients who do not stay beyond their HRG 
trimpoint. 
x Fully specialised: excluding from the analysis those patients in HRGs in which everyone 
receives specialised care (100% specialised) or in which nobody does (100% non-
specialised). 
x Eligibility: dropping the requirement that specialised care is defined as being provided in 
eligible providers only. 
x Partial matches: including patients with partially matched Reference Cost data in the 
analytical sample.  
 
Using FCEs as the unit of analysis 
The basic unit of observation in HES is the FCE.  We convert FCEs into provider spells and use these 
as the basic unit of observation for the analysis, the primary reason being that tariffs under PbR are 
spell-based.  Recognising that there may be possible concerns about how we have constructed spells 
or calculated the cost of spells, we conduct a sensitivity analysis using FCEs as the unit of analysis. 
 
Inlier sample 
The base tariff is paid for patients who are discharged from hospital before HRG-specific length of 
stay trimpoints (so-called inliers).  For patients that stay beyond the trimpoint, payment includes the 
base tariff plus an excess bedday payment for each additional day in hospital above the trimpoint. 
Top-up payments, where currently applicable, are made to the base HRG tariff and to excess bedday 
payments. 
 
Given this payment policy, it is important to be reassured that cost differentials are observed for 
these inlier patients.  If cost differentials are observed solely for those that stay beyond the 
trimpoint, payment policy should be to have differential excess bedday rates, but not differential 
base tariffs.  This sensitivity analysis examines whether cost differentials are observed for inlier 
patients. 
 
Fully specialised HRGs 
The construction of some HRGs means that everyone allocated to them receives specialised care.  
This is because the HRG itself is defined using the ICD or OPCS codes that are also used as indicators 
of specialised care.  Conversely, some HRGs contain no patients that received specialised care.  The 
HRGs where either situation occurs are listed in Table 7. 
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Table 7 HRGs in which everyone (100%) or no-one (0%) is classified as having received specialised care under 
the SSNDS and PSS definitions 
100% 
 
0% 
SSNDS 
 
PSS 
 
SSNDS PSS 
AA04B HC09Z 
 
BZ08B 
 
AA27B DZ15C 
AA11B LA01A 
 
BZ09B 
 
AB10Z DZ27C 
AA12A LA01B 
 
CZ25N 
 
DZ34Z DZ34Z 
AA28A LA02A 
 
CZ25Q 
 
DZ35Z DZ36Z 
AA28B LA02B 
 
CZ27Z 
 
DZ41Z DZ41Z 
CZ25N LA03A 
 
CZ28Z 
 
HA39Z DZ52Z 
CZ25Q LA03B 
 
DZ21D 
 
HA79Z GA10E 
CZ27Z LA10Z 
 
DZ43Z 
 
HD39C HA39Z 
CZ28Z LA11Z 
 
DZ46Z 
 
JC13Z HA59Z 
CZ35Y LA12A 
 
EA01Z 
 
JD02C HA69Z 
DZ01Z LB46Z 
 
EA24Z 
 
LB28B HA79Z 
DZ18Z QZ23Z 
 
EA26Z 
 
LB73Z JA31Z 
DZ21D RC41Z 
 
FZ24F 
 
MC06Z JC13Z 
DZ31Z RC42Z 
 
FZ42B 
 
MC11Z JC19D 
DZ33Z SA14Z 
 
FZ83E 
 
MC12Z KB02C 
DZ36Z SA15Z 
 
FZ85Z 
 
PA55Z LA12A 
DZ43Z SA16Z 
 
GA01A 
 
QZ21B LB73Z 
DZ46Z SA19A 
 
GA01B 
 
RC03Z MA17D 
DZ52Z SA19B 
 
GA10G 
 
WA04U MA19B 
EA01Z SA20A 
 
GB04E 
 
WA10Z MA20Z 
EA02Z SA20B 
 
LA01B 
 
WA15K MB02Z 
EA12Z SA21B 
 
LA02B 
 
WA15L MC06Z 
EA14Z SA22A 
 
LA03B 
 
WA15M MC11Z 
EA16Z SA22B 
 
LA11Z 
 
WA15N MC12Z 
EA19Z SA23A 
 
PA40A 
 
WA15O QZ21A 
EA22Z SA23B 
 
PA40B 
 
WA15P QZ21B 
EA23Z SA26A 
 
SA19A 
 
WA15V RC01Z 
EA24Z SA26B 
 
SA19B 
 
WA23Y RC03Z 
EA26Z SA27A 
 
SA20A 
  
SA03F 
EA43Z SA27B 
 
SA20B 
  
WA01Y 
EA51Z SA28A 
 
SA21A 
  
WA10Z 
EA52Z SA28B 
 
SA21B 
  
WA15K 
EA53Z WA01W 
 
SA22A 
  
WA15M 
EA55Z WA01Y 
 
SA22B 
  
WA15N 
FZ24F 
  
SA23A 
  
WA15P 
FZ72Z 
  
SA23B 
  
WA23Y 
FZ83E 
  
SA26A 
   FZ84Z 
  
SA26B 
   FZ85Z 
  
SA27A 
   FZ88B 
  
SA27B 
   GA01A 
  
SA28A 
   GA01B 
  
SA28B 
    
For the HRGs in question the base tariff will properly account for the costs of specialised (or non-
specialised) care so no further top-up adjustment is necessary.  Retaining patients allocated to these 
HRGs in the analysis might be inappropriate for the estimation of the influence of specialised care 
for patients allocated to other HRGs.  This is because there will no cost differential for those in fully 
specialised HRGs, so including them in the analysis will dilute the difference for those HRGs 
comprising a mix of patients that do or do not receive specialised care. 
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Dropping patients in those HRGs in which everyone is identified as having received specialised care 
and those HRGs in which no-one is identified as having received specialised care reduces the 
analytical sample by 1.9% (256,861 spells). 
Eligible providers 
Some hospitals have been designated as eligible for top-up payments for some specialised services, 
and eligibility arrangements are also embodied in the PSS toolkit.  Hospitals that satisfy the eligibility 
criteria undertake more specialised spells than do other hospitals. 
 
For the PSS service lines listed below, a patient is defined as receiving specialised care if their 
medical record triggers any of the PSS identification rules and they were treated at an eligible 
provider.  We assess the sensitivity of results to relaxation of the condition that specialised services 
have to be delivered by eligible providers, so that these PSS markers are assigned on the basis of the 
ICD10 or OPCS codes alone.  
 
x B05  - Haemophilia 
x D14 - Spinal - Spinal Surgery 
x D03 - Neurosciences - Neurosurgery 
x A01 - Cystic fibrosis 
x A10 - Cardiac - Cardiac surgery 
x A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 
x A11 - Cardiac - Pulmonary hypertension 
x D07 - Cleft Lip Palate 
x B07 - Infectious Diseases Adult 
x A03d - Respiratory - Interstitial lung disease 
  
Partially matched cost data 
As described in the previous section, we define two analytical samples.  Our baseline analytical 
sample comprises a total of 14,184,683 FCEs and consists of those for which we secure a Best match 
between HES and Reference Cost data.  
 
As a sensitivity analysis, we assess the impact of including partially matched data, which increases 
the sample to 15,234,491 FCEs. We do not conduct this analysis for spell-based data. 
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4. Descriptive statistics 
The numbers of patients identified as having received specialist care as defined by the SSNDS and for 
which costs are available are reported in Table 8, for both 2009/10 and 2011/12, and the number of 
spells in the full HES dataset for 2011/12 identified as having received each type of specialised care. 
 
In 2009/10, costs were available for 1,440,351 patients who received specialised care, whereas the 
corresponding number was 1,285,069 in 2011/12.  The reduction is driven by those identified as 
having specialised renal care, the number falling from 510k in 2009/10 to 35k in 2011/12.  This is due 
to costs for renal patients not being discretely identifiable in the 2011/12 RC submission (some 
501,863 patients received specialised renal care in 2011/12, as seen in Table 2).  For most other 
types of specialised care, numbers are fairly similar over time or have increased.  The most notable 
volume increases are for cystic fibrosis (60k), cardiology (26k), children (80k) and respiratory (103k). 
The main reasons for a change in the volumes over time are: 
 
x Changes in clinical practice 
x Changes in coding practice and in the underlying primary classifications used for coding, as 
identification of specialised care requires accurate coding of ICD10 and OPCS codes 
x Changes in costing practice and in our ability to map reported costs to individual patients 
 
Table 8 Number of patients receiving SSNDS specialised services for which  ?ďĞƐƚ ?cost matches are available 
and cleaned HES sample 
 
 
The number of patients (spells) receiving specialised care as defined using the PSS definitions is 
shown in Table 9 ?ĨŽƌďŽƚŚƚŚŽƐĞǁŝƚŚ “Best ?ŵĂƚĐŚĞĚĐŽƐƚƐĂŶĚĨŽƌƚŚĞĨƵůůcleaned HES dataset.  As 
can be seen, there is large variation in the numbers of patients in each PSS chapter, with some 
populated by very few patients nationally (some have fewer than 300 spells).  For such poorly 
populated PSS chapters, the cost estimates are likely to be imprecisely estimated. 
2009/10 2011/12 2011/12
SSNDS chapter SSNDS label Full sample Full sample HES sample
Spells Spells Spells
n n n
Specialised cancer services (adult) Cancer 11,907 11,252             22,487             
Specialised services for blood and marrow transplantation (all aBMT 364 363                   580                   
Specialised services for haemophilia and other related bleedingHaemophilia 153 420                   452                   
6SHFLDOLVHGVHUYLFHVIRUZRPHQ¶VKHDOWKDGXOW Womens 24,389 26,000             30,100             
Specialised spinal services (all ages) Spinal 2,507 11,933             14,753             
Specialised neurosciences services (adult) Neurosciences 26,204 26,034             37,873             
Cystic fibrosis services (all ages) CysticFibrosis 101,770 161,432           252,100           
Specialised renal services (adult) Renal 510,847 35,860             493,968           
Specialised intestinal failure and home parenteral nutrition servicIntestinalFailure 2,246 1,918                2,855                
Specialised cardiology and cardiac surgery services (adult) Cardiology 90,381 116,332           163,125           
Cleft lip and palate services (all ages) CleftLip 238,141 243,449           270,293           
Specialised services for infectious diseases (all ages) InfectiousDiseases 2,039 1,498                1,908                
Specialised services for liver, biliary and pancreatic medicine anLiver 12,244 23,906             57,221             
Specialised services for children Children 131,657 211,774           302,537           
Specialised dermatology services (all ages) Dermatology 12,298 8,952                10,554             
Specialised rheumatology services (all ages) Rheumatology 338 1,040                1,459                
Specialised endocrinology services (adult) Endocrinology 7,306 6,777                9,316                
Specialised respiratory services (adult) Respiratory 68,374 172,142           223,440           
Specialised vascular services (adult) VascularDiseases 1,215 1,798                2,847                
Specialised pain management services (adult) PainManagement 1,266 1,227                1,321                
Specialised ear services (all ages) EarSurgery 1,655 2,715                2,872                
Specialised colorectal services (adult) Colorectal 7,355 8,921                11,065             
Specialised orthopaedic services (adult) Orthopaedic 4,207 5,006                5,589                
Specialised morbid obesity services (all ages) MorbidObesity 11,458 15,018             17,439             
Specialised services for metabolic disorders (all ages) New for 3MetabolicDisorders 3,236 3,775                4,512                
Specialised ophthalmology services (adult) New for 3rd edition Ophtalmology 7,006 7,792                8,195                
Specialised haemoglobinopathy services (all ages) New for 3rdHaemoglobinopathy 159,788 177,735           190,196           
Specia lised sample 1,440,351 1,285,069 2,139,057   
More than 1 SSNDS 35,972 93,694
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Table 9 Number of patients receiving PSS specialised services for which  ?ďĞƐƚ ?costs are available and 
cleaned HES sample 
 
PSS chapter PSS label Full sample HES sample
Spells Spells
n n
B03 - Chemotherapy NCBPS01C 47,186             667,666           
B02 - PET-CT NCBPS01P 4                       754                   
B01 - Radiotherapy NCBPS01R 7,363               78,809             
D05 - Stereotactic Radiosurgery NCBPS01S 192                   1,397                
B03 - Teenage and Young Adults Cancer NCBPS01T 6,829               14,285             
B03 - Rare Cancers (Adult) NCBPS01Y 29,364             60,504             
B04 - BMT NCBPS02Z 1,846               3,047                
B05  - Haemophilia NCBPS03Z 3,559               4,391                
E10 - Women - Complex Minimal Access Gynaecology Surgery NCBPS04A 1,274               1,526                
E12 - Women - Fetal Medicine NCBPS04C 168                   181                   
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse NCBPS04D 14                     16                     
E11 - Women - Maternal Medicine (complications of pregnancy) NCBPS04E 39,629             44,238             
D14 - Spinal - Spinal Surgery NCBPS06Z 6,333               8,141                
D04 - Neurosciences - Neurology NCBPS08O 96,650             123,506           
D04 - Neurosciences - Neurophysiology NCBPS08P 87                     175                   
D04 - Neurosciences - Neuroradiology NCBPS08R 13                     32                     
D03 - Neurosciences - Neurosurgery NCBPS08S 54,455             71,463             
D06 - Burns Care NCBPS09Z 2,948               5,738                
A01 - Cystic fibrosis NCBPS10Z 646                   11,061             
A06 - Renal Services - Access for dialysis NCBPS11C 13,323             15,835             
A07  - Renal Services - Renal Transplantation NCBPS11T 9,296               10,602             
A09 - Cardiac - Cardiac electrophysiology NCBPS13B 5,671               6,863                
A09 - Cardiac - Inherited heart disorders NCBPS13C 3,955               5,957                
A10 - Cardiac - Cardiac surgery NCBPS13E 24,744             41,862             
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) NCBPS13F 25,910             41,247             
A11 - Cardiac - Pulmonary hypertension NCBPS13G 3,292               4,367                
A10 - Cardiac - Cardiovascular magnetic resonance NCBPS13H 8                       4,549                
A10 - Cardiac - Other NCBPS13K 15,791             20,397             
A13 - Adult Congenital Heart Disease NCBPS13X 4,185               6,992                
D07 - Cleft Lip Palate NCBPS15Z 2,695               2,843                
B09 - Immunology NCBPS16Z 9,760               10,975             
B09 - Allergy NCBPS17Z 1,971               2,538                
B07 - Infectious Diseases Adult NCBPS18A 268                   312                   
B07 - Infectious Diseases Paeds NCBPS18C 247                   2,365                
A02 - Hepatology & Pancreatic NCBPS19Z 2,342               4,073                
C04 - Mental Health - Gender Dysphoria NCBPS22Z 160                   163                   
E04 - Childrens services - Cancer NCBPS23A 25,405             55,676             
E05 - Childrens services - Cardiac NCBPS23B 8,645               18,326             
E03 - Childrens services - Endocrinology NCBPS23E 3,671               3,933                
E03 - Childrens services - Gastroenterology NCBPS23F 62,385             79,516             
E03 - Childrens services - Haematology NCBPS23H 1,919               2,373                
E09 - Childrens services - Neurosciences NCBPS23M 9,071               16,615             
E03 - Childrens services - Ophthalmology NCBPS23N 6,725               8,055                
E03 - Childrens services - Renal NCBPS23S 9,593               13,947             
E03 - Childrens services - Respiratory NCBPS23T 7,184               9,749                
E03 - Childrens services - Rheumatology NCBPS23W 6,047               8,017                
E02 - Childrens services - Surgery NCBPS23X 44,589             63,719             
E03 - Childrens services - Paediatric Pain Management NCBPS23Y 25                     25                     
D11 - Hyperbaric Oxygen Treatment NCBPS28Z 12                     17                     
A03d - Respiratory - Pulmonary vascular services NCBPS29A 178                   274                   
A12 - Respiratory - Complex thoracic surgery NCBPS29B 27,615             41,886             
A03d - Respiratory - Management of central airway obstruction NCBPS29E 1,901               3,127                
A03d - Respiratory - Interstitial lung disease NCBPS29M 2,534               3,490                
A03d - Respiratory - Other NCBPS29R 13,953             23,733             
A04 - Vascular Services NCBPS30Z 4,839               7,422                
D09 - Ears - Cochlear Implants NCBPS32A 1,150               1,250                
D09 - Ears - Bone anchored hearing aids NCBPS32B 1,370               1,388                
D09 - Ears - Middle Ear Implants NCBPS32D 113                   119                   
A08 - Colorectal - Complex Surgery for Incontinence NCBPS33A 1,090               1,692                
A08 - Colorectal - Complex Inflammatory Bowel disease NCBPS33B 63                     88                     
A08 - Colorectal - Transanal Endoscopic Microsurgery NCBPS33C 503                   535                   
D10 - Orthopaedic Surgery NCBPS34A 1,637               2,006                
D10 - Orthopaedic Surgery - revisions NCBPS34R 176                   187                   
A05 - Morbid Obesity Surgery NCBPS35Z 8,252               9,169                
D12 - Ophthalmology NCBPS37Z 20,004             20,840             
B08 - Haemoglobinopathy - Sickle Cell NCBPS38S 13,553             13,946             
B08 - Haemoglobinopathy - Thalassaemia NCBPS38T 8,651               8,873                
Highly Specialised NCBPS99Z 11,355             17,382             
Specia lised sample 726,386      1,716,245
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In Table 10 we summarise the number of observations used in each of the regression analyses, and 
the number identified as having received specialised services under each definitional type (SSNDS or 
PSS). Note that patients can have more than one specialised service.  The counts below include such 
patients.   
 
Table 10 Summary of analytical samples 
Analysis type 
Unit of 
observation 
SSNDS Total 
sample 
Of which 
specialised 
PSS Total 
sample 
Of which 
specialised 
Baseline Spell 
         
12,286,246  1,285,069 
         
12,286,246  
         
726,386  
Inlier sample Spell 
         
11,927,415  1,232,716 
         
11,927,415  
         
692,779  
Full sample FCE 
         
14,184,683  1,437,072 
         
14,184,683  
         
784,507  
Inlier sample FCE 
         
13,779,336  1,381,977 
         
13,779,336  
         
748,324  
PSS toolkit FCE 
  
         
14,184,683  
         
750,894  
Drop 100% & 0% Spell 
        
12,228,578  1,234,398 
         
12,244,417  
         
709,903  
Eligibility Spell 
  
         
12,286,246  
         
747,022  
Partail match FCE 
  
         
15,234,491  
         
862,407  
Random effects Spell 
        
12,286,246  1,285,069 
         
12,286,246  
         
726,386  
Note: counts of the number of specialised FCEs and spells differ from Table 1 because patients can have more than one 
specialised service 
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5. Results 
5.1 Introduction  
We have estimated various equations and explored the sensitivity of estimates to a range of 
modelling choices.  In reporting the results, we focus on the estimates associated with the 
specialised markers, defined first using SSNDS and then by PSS.  Rather than reporting the 
coefficients, we report the predicted percentage difference in costs for patients who received 
specialised care compared to those that did not.  The specialised markers where estimates are 
statistically significant appear in bold if p<0.001.  
 
5.2 SSNDS analyses 
Baseline analysis 
In Table 11 we report the numbers and percentage cost differences for each of the SSNDS markers 
for 2009/10 and 2011/12.  These are derived from estimating equation 1: ݕ௜ ൌן ൅  ? ߚ௡ܵ௡௜ ൅ ߝ௜ே௡ୀଵ  
 
These results ĨŽƌŵŽƵƌ “ďĂƐĞůŝŶĞ ?^^E^ĂŶĂůǇƐŝƐĂŶĚare comparable across the two years, sharing 
the following core features: 
 
x All observations for which costs are Best matched are included 
x Each observation represents a spell (rather than FCE) 
x The cost of a spell is calculated as the sum of the cost of the constituent episodes 
x Each patient is assigned a specialist marker if one of the SSNDS ICD10 or OPCS codes appears 
in their record
d
  
x The model is estimated using OLS and does not account for clustering within providers. 
 
Changes can be expected in the estimated cost differentials over time. These will be due to a 
combination of clinical, coding and costing factors that have driven changes over time in the volume 
of patients identified as having received specialised care and in how their costs have been identified, 
and in changes to the HRG casemix classification that might have changed the resource homogeneity 
of the underlying groups to which patients are categorised; 
 
The main messages from these comparisons are the following: 
 
x For 13 of the 27 of the SSNDS markers, estimated cost differences are stable across the two 
years, even for some of those SSNDS markers where there have been large changes in the 
number of patients identified as having received specialised care; 
 
x There are 8 of the 27 markers that appear significant in 2011/12 but that were not in 
2009/10.  For almost all of these, there are substantive differences in the volume of patients 
identified as having received these particular types of specialised care between the two 
years.  
 
x For 4 of the 27 markers, the cost differential between those that received specialised care 
and those that did not is lower in 2011/12 than it was in 2009/10. This is apparent for 
Neurosciences, where the difference has fallen from 28% to 13%, despite little change in the 
number identified as having received such care.  The cost difference for Children has fallen 
from 30% to 15%, which may be partly due to the increased volume from 132k to 212k.  For 
                                                     
d
 The 2009/10 assignment also conditions upon the patient being treated at provider considered eligible by the 
Department of Health to provide specialised services 
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Liver, the number has almost doubled, and the cost difference has fallen from 13% to 3%. 
For Infectious Diseases, there has been 25% reduction in volume, with the cost differential 
falling from 41% to 29%. Overall, then, there is no clear relationship between changes in 
volume and the change in the cost differential. More detailed work would be required to 
understand the reasons for the volume changes and about the particular characteristics of 
the patients designated as having received specialised care in each time period. 
 
x For 2 of the 27 markers, the cost differentials have increased. These are Rheumatology and 
Vascular Diseases, and for both of these there has been an increase in the number identified 
as having received such specialised services.  
 
Table 11 ŽŵƉĂƌŝƐŽŶŽĨ ?ďĂƐĞůŝŶĞ ?ƌĞƐƵůƚƐĨŽƌ ? ? ? ? ? ? ?ĂŶĚ ? ? ? ?  ?  
 
 
Sensitivity analyses: inliers and FCEs 
We assess whether the cost differences for each of the SSNDS markers are sensitive to various 
analytical choices.  In the first two columns of Table 12, we repeat the results of our baseline 
analysis.  This is followed by three sets of two columns reporting volumes and percentage cost 
differences for the following choices: 
 
2009/10 2011/12
SSNDS label Full sample Full sample Full sample Full sample Increase
Spells Spells Spells Spells over time
n % n % %
[a]
Cancer 11,907 31% 11,252             36% 5%
BMT 364 -4% 363                   -6% -3%
Haemophilia 153 -13% 420                   -6% 7%
Womens 24,389 6% 26,000             1% -6%
Spinal 2,507 14% 11,933             17% 3%
Neurosciences 26,204 28% 26,034             13% -15%
CysticFibrosis 101,770 36% 161,432           35% -1%
Renal 510,847 23% 35,860             21% -2%
IntestinalFailure 2,246 0% 1,918                7% 7%
Cardiology 90,381 12% 116,332           10% -2%
CleftLip 238,141 3% 243,449           0% -4%
InfectiousDiseases 2,039 41% 1,498                29% -12%
Liver 12,244 13% 23,906             3% -9%
Children 131,657 30% 211,774           15% -15%
Dermatology 12,298 0% 8,952                -22% -22%
Rheumatology 338 33% 1,040                46% 13%
Endocrinology 7,306 6% 6,777                11% 5%
Respiratory 68,374 8% 172,142           1% -7%
VascularDiseases 1,215 34% 1,798                41% 7%
PainManagement 1,266 225% 1,227                243% 17%
EarSurgery 1,655 8% 2,715                0% -8%
Colorectal 7,355 13% 8,921                11% -2%
Orthopaedic 4,207 16% 5,006                12% -5%
MorbidObesity 11,458 -7% 15,018             -1% 6%
MetabolicDisorders 3,236 43% 3,775                91% 48%
Ophtalmology 7,006 7% 7,792                10% 3%
Haemoglobinopathy 159,788 6% 177,735           2% -4%
T ota l sample 12,971,384 12,286,246 
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x Using spells as the unit of observation, but limiting the analytical sample to inliers, defined 
as those whose length of stay did not exceed their HRG-specific LoS trimpoint; 
x Using FCEs as the unit of observation, but using the full sample; 
x Using FCEs as the unit of observation, but again limiting the analytical sample to inliers. 
 
Note that a cost denominator specific to each analytical sample is defined in constructing the 
standardised cost for each of these analyses.  This means that the cost differences refer to different 
 “ďĂƐĞ ?ĐŽƐƚƐŝŶĞĂĐŚĂŶĂůǇƐŝƐ ?ƐŽƚŚĞƐŝǌĞŽĨƚŚĞ cost differences are not exactly comparable across 
models. 
 
Table 12 Analyses for inlier samples and using FCEs 
 
 
The main messages from these comparisons are the following: 
 
x The cost differences are robust to whether the unit of observation is based on spells or FCEs.  
This is evident from comparing columns [a] with [c] (for the full sample) and [b] with [d] (for 
inliers).  The difference between the two sets of estimates never exceeds 5% for either the 
full or inlier sample. 
 
x The significance (and, often, size) of the cost differences is not particularly sensitive to 
whether analysis is conducted on the full sample or just inliers.  This is evident from 
comparing columns [a] and [b] for the analyses based on spells (and columns [c] and [d] for 
the analyses based on FCEs).  This is reassuring because it suggests that cost differences are 
not driven solely by patients with excessive lengths of stay. 
 
x For two SSNDS markers the cost difference is higher for the full sample than for the inlier 
sample, these being Cystic Fibrosis (21% difference) and Infectious Disease (13%).  For five 
others the difference is more than 5% higher for the full sample (Spinal, Neurosciences, 
Renal, Vascular Disease and Orthopaedics).  This suggests that, for these seven markers, 
2011/12
SSNDS label Full sample Full sample Inlier sample Inlier sample Full sample Full sample Inlier sample Inlier sample
Spells Spells Spells Spells FCEs FCEs FCEs FCEs
n % n % n % n %
[a] [b] [c] [d]
Cancer 11,252             36% 10,577             33% 13,166             34% 12,414             32%
BMT 363                   -6% 350                   -1% 371                   -12% 362                   -5%
Haemophilia 420                   -6% 415                   -5% 424                   -6% 419                   -5%
Womens 26,000             1% 25,361             4% 26,963             2% 26,316             6%
Spinal 11,933             17% 10,920             9% 12,412             16% 11,397             10%
Neurosciences 26,034             13% 24,371             7% 27,416             12% 25,732             7%
CysticFibrosis 161,432           35% 144,702           14% 184,383           32% 167,223           9%
Renal 35,860             21% 34,260             16% 40,392             20% 38,678             15%
IntestinalFailure 1,918                7% 1,800                9% 2,188                4% 2,064                7%
Cardiology 116,332           10% 110,328           9% 130,680           7% 124,263           7%
CleftLip 243,449           0% 241,000           4% 244,567           1% 242,050           6%
InfectiousDiseases 1,498                29% 1,409                16% 1,789                26% 1,693                14%
Liver 23,906             3% 23,007             4% 34,332             3% 33,223             4%
Children 211,774           15% 205,743           13% 224,383           15% 217,710           13%
Dermatology 8,952                -22% 8,853                -23% 9,074                -21% 8,972                -21%
Rheumatology 1,040                46% 1,003                47% 1,058                43% 1,020                45%
Endocrinology 6,777                11% 6,497                13% 7,050                11% 6,745                13%
Respiratory 172,142           1% 160,848           -3% 249,020           1% 237,002           -4%
VascularDiseases 1,798                41% 1,684                35% 1,931                38% 1,817                34%
PainManagement 1,227                243% 1,155                266% 1,229                238% 1,155                265%
EarSurgery 2,715                0% 2,562                5% 2,726                0% 2,574                6%
Colorectal 8,921                11% 8,640                12% 10,155             12% 9,830                14%
Orthopaedic 5,006                12% 4,595                6% 5,064                13% 4,657                8%
MorbidObesity 15,018             -1% 14,489             2% 15,850             1% 15,308             4%
MetabolicDisorders 3,775                91% 3,707                93% 3,891                88% 3,813                92%
Ophtalmology 7,792                10% 7,529                11% 7,803                12% 7,539                13%
Haemoglobinopathy 177,735           2% 176,911           7% 178,755           2% 178,001           8%
T ota l sample 12,286,246 11,927,415 14,184,683 13,779,336 
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observed cost differentials between patients who do and do not receive specialised care are 
more pronounced for those who stay beyond the LoS trimpoint. 
 
x For only one SSNDS marker (Pain Management) is the difference markedly lower for the full 
sample than for the inlier sample (-23% difference). 
 
Sensitivity analysis: omitting fully and non-specialised HRGs  
There are 76 HRGs in which everyone received some form of specialised care as defined by the 
SSNDS and 28 HRGs in which nobody did.  If patients allocated to these HRGs are omitted, 57,668 
spells are dropped from the analytical sample.  The impact that this has on the results is reported in 
Table 13.  With the exception of that for Pain Management, none of percentage effects change 
notably for any of the SSNDS markers. 
 
Table 13 Sensitivity analysis to omission of fully or non-specialised HRGs 
  
  
2011/12
SSNDS label Full sample Full sample Drop 100% & 0% Drop 100% & 0%
Spells Spells Spells Spells
n % n %
[a] [e]
Cancer 11,252             36% 11,240                    36%
BMT 363                   -6% 63                            -1%
Haemophilia 420                   -6% 419                          -6%
Womens 26,000             1% 25,967                    1%
Spinal 11,933             17% 11,909                    17%
Neurosciences 26,034             13% 24,181                    14%
CysticFibrosis 161,432           35% 156,411                  35%
Renal 35,860             21% 33,820                    23%
IntestinalFailure 1,918                7% 1,916                       7%
Cardiology 116,332           10% 95,065                    13%
CleftLip 243,449           0% 243,370                  0%
InfectiousDiseases 1,498                29% 1,497                       29%
Liver 23,906             3% 23,900                    3%
Children 211,774           15% 210,163                  15%
Dermatology 8,952                -22% 8,941                       -23%
Rheumatology 1,040                46% 1,039                       46%
Endocrinology 6,777                11% 6,746                       11%
Respiratory 172,142           1% 166,202                  1%
VascularDiseases 1,798                41% 1,670                       45%
PainManagement 1,227                243% 1,134                       262%
EarSurgery 2,715                0% 279                          -8%
Colorectal 8,921                11% 8,921                       11%
Orthopaedic 5,006                12% 5,006                       12%
MorbidObesity 15,018             -1% 7,372                       -2%
MetabolicDisorders 3,775                91% 3,761                       91%
Ophtalmology 7,792                10% 7,792                       10%
Haemoglobinopathy 177,735           2% 175,614                  2%
T ota l sample 12,286,246 12,228,578      
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Accounting for hospital effects 
Table 14 compares results from equation 1: ݕ௜ ൌן ൅  ? ߚ௡ܵ௡௜ ൅ ߝ௜ே௡ୀଵ  which is estimated using OLS 
and where no account is taken of the hospital in which treatment took place with equation 2: ݕ௜௞ ൌן ൅  ? ߚ௡ܵ௡௜௞ ൅ ݑ௞ ൅ ݒ௜௞ே௡ୀଵ  which accounts for hospital clustering using a random effects 
specification.  The table provides estimates of the cost differences associated with the SSNDS 
markers for each of these specifications. 
 
The cost differences are always larger for the OLS model than the RE model that accounts for 
clustering.  This is because, in the former model, some of the observed cost differences attributed to 
the receipt of specialised care are actually related to the hospital in which treatment took place.  The 
better specified RE model apportions costs more accurately because it accounts for this clustering. 
 
We recommend that, if required, top-up arrangements should be calculated on the basis of results 
from the RE model that takes account of hospital effects. 
 
Table 14 Comparison of OLS and RE models 
 
 
  
2011/12
SSNDS label Full sample Full sample Full sample
Spells OLS Spells OLS Spells RE
n % %
[a] [f]
Cancer 11,252             36% 29%
BMT 363                   -6% -18%
Haemophilia 420                   -6% -16%
Womens 26,000             1% 0%
Spinal 11,933             17% 11%
Neurosciences 26,034             13% 8%
CysticFibrosis 161,432           35% 32%
Renal 35,860             21% 16%
IntestinalFailure 1,918                7% 7%
Cardiology 116,332           10% 5%
CleftLip 243,449           0% -1%
InfectiousDiseases 1,498                29% 25%
Liver 23,906             3% 0%
Children 211,774           15% 6%
Dermatology 8,952                -22% -23%
Rheumatology 1,040                46% 24%
Endocrinology 6,777                11% 7%
Respiratory 172,142           1% -1%
VascularDiseases 1,798                41% 34%
PainManagement 1,227                243% 221%
EarSurgery 2,715                0% -8%
Colorectal 8,921                11% 8%
Orthopaedic 5,006                12% 4%
MorbidObesity 15,018             -1% -2%
MetabolicDisorders 3,775                91% 67%
Ophtalmology 7,792                10% 9%
Haemoglobinopathy 177,735           2% 2%
T ota l sample 12,286,246
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5.3 PSS analyses 
Baseline analysis 
In Table 15 we report the numbers and cost differences for each of the PSS markers for 2011/12. 
These estimates are based on data with the following features: 
 
x All observations for which  “Best ?ŵĂƚĐŚĞĚReference Costs are available are included. 
x Each observation represents a spell (rather than FCE).  
x The cost of a spell is calculated as the sum of the cost of the constituent episodes 
x Each patient is assigned a specialist marker if one of the PSS ICD10 or OPCS codes appears in 
their record and they were treated at an eligible provider. 
x The model is estimated using OLS and does not account for clustering within providers. 
 
Two sets of estimates are provided 
 
x The first uses the full sample  W column [a] 
x The second limits the analytical sample to inliers (ie those whose length of stay did not 
exceed their HRG defined LoS trimpoint)  W column [b] 
 
The main messages are as follows: 
 
x Most of the PSS markers are positive and significant, implying that patients who received 
specialised care of the type indicated had higher costs than other patients allocated to the 
same HRG; 
 
x For the majority of PSS markers the above is true whether we look at the full sample or just 
the inlier sample. This suggests that it is reasonable to apply a top-up adjustment, if merited, 
to the base tariff; 
 
x For some PSS markers the financial implications of the cost differences will be small, partly 
because only small volumes of patients received the specialised care in question (eg B02-
PET-CT) or because the cost differences are small; 
 
x For a handful of PSS markers the cost differences are negative, suggesting such patients 
have lower costs than comparable patients that did not receive specialised care. This might 
be contrary to expectations, so these PSS markers repay further scrutiny to see whether the 
negative effects are sensitive to specification choices. In particular, the cost differences 
reported here do not account for the cost implications associated with clustering of patients 
within hospitals. These provider-level effects may be important at explaining cost 
differences among patients over and above the provision of specialised care. 
 
x For those markers with more than 300 patients in the analysis and that are statistically 
significant, the cost differential between those that do and do not receive specialised care is 
more than 10% for 33 PSS markers; for 21 of these the difference is more than 25%; and for 
11 it is more than 50%. 
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  Table 15 Baseline and inlier analyses based on spells 
 
 
 
PSS chapter Full sample Full sample Inlier sample Inlier sample
Spells Spells Spells Spells
n % n %
[a] [b]
B03 - Chemotherapy 47,186             50% 47,007             53%
B02 - PET-CT 4                       483% 2                        249%
B01 - Radiotherapy 7,363               129% 6,760                117%
D05 - Stereotactic Radiosurgery 192                   -182% 189                   -168%
B03 - Teenage and Young Adults Cancer 6,829               31% 6,682                28%
B03 - Rare Cancers (Adult) 29,364             22% 27,734             20%
B04 - BMT 1,846               -5% 1,790                -4%
B05  - Haemophilia 3,559               80% 3,503                79%
E10 - Women - Complex Minimal Access Gynaecology Surgery 1,274               -8% 1,263                -6%
E12 - Women - Fetal Medicine 168                   0% 163                   -14%
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 14                     83% 14                     89%
E11 - Women - Maternal Medicine (complications of pregnancy) 39,629             11% 37,695             7%
D14 - Spinal - Spinal Surgery 6,333               -1% 5,692                -4%
D04 - Neurosciences - Neurology 96,650             43% 91,723             34%
D04 - Neurosciences - Neurophysiology 87                     -34% 85                     -42%
D04 - Neurosciences - Neuroradiology 13                     -43% 13                     -41%
D03 - Neurosciences - Neurosurgery 54,455             41% 50,758             37%
D06 - Burns Care 2,948               71% 2,755                47%
A01 - Cystic fibrosis 646                   25% 638                   29%
A06 - Renal Services - Access for dialysis 13,323             59% 11,968             32%
A07  - Renal Services - Renal Transplantation 9,296               -1% 8,846                -3%
A09 - Cardiac - Cardiac electrophysiology 5,671               1% 5,266                1%
A09 - Cardiac - Inherited heart disorders 3,955               53% 3,489                26%
A10 - Cardiac - Cardiac surgery 24,744             24% 23,029             22%
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 25,910             25% 24,392             27%
A11 - Cardiac - Pulmonary hypertension 3,292               29% 3,107                13%
A10 - Cardiac - Cardiovascular magnetic resonance 8                       52% 3                        27%
A10 - Cardiac - Other 15,791             5% 15,252             5%
A13 - Adult Congenital Heart Disease 4,185               6% 4,073                6%
D07 - Cleft Lip Palate 2,695               10% 2,615                11%
B09 - Immunology 9,760               12% 9,737                14%
B09 - Allergy 1,971               -13% 1,971                -8%
B07 - Infectious Diseases Adult 268                   -38% 258                   -43%
B07 - Infectious Diseases Paeds 247                   33% 239                   -2%
A02 - Hepatology & Pancreatic 2,342               8% 2,214                10%
C04 - Mental Health - Gender Dysphoria 160                   30% 159                   35%
E04 - Childrens services - Cancer 25,405             12% 25,056             13%
E05 - Childrens services - Cardiac 8,645               44% 8,054                36%
E03 - Childrens services - Endocrinology 3,671               8% 3,657                14%
E03 - Childrens services - Gastroenterology 62,385             16% 60,427             10%
E03 - Childrens services - Haematology 1,919               32% 1,879                32%
E09 - Childrens services - Neurosciences 9,071               73% 8,564                54%
E03 - Childrens services - Ophthalmology 6,725               4% 6,637                5%
E03 - Childrens services - Renal 9,593               31% 9,407                26%
E03 - Childrens services - Respiratory 7,184               73% 6,825                67%
E03 - Childrens services - Rheumatology 6,047               11% 5,784                9%
E02 - Childrens services - Surgery 44,589             13% 42,754             14%
E03 - Childrens services - Paediatric Pain Management 25                     150% 25                     162%
D11 - Hyperbaric Oxygen Treatment 12                     139% 9                        43%
A03d - Respiratory - Pulmonary vascular services 178                   -32% 164                   -30%
A12 - Respiratory - Complex thoracic surgery 27,615             43% 25,967             45%
A03d - Respiratory - Management of central airway obstruction 1,901               68% 1,760                62%
A03d - Respiratory - Interstitial lung disease 2,534               -10% 2,499                -7%
A03d - Respiratory - Other 13,953             22% 12,107             9%
A04 - Vascular Services 4,839               17% 4,499                13%
D09 - Ears - Cochlear Implants 1,150               -6% 1,040                -2%
D09 - Ears - Bone anchored hearing aids 1,370               0% 1,342                2%
D09 - Ears - Middle Ear Implants 113                   -12% 108                   -10%
A08 - Colorectal - Complex Surgery for Incontinence 1,090               -42% 1,087                -41%
A08 - Colorectal - Complex Inflammatory Bowel disease 63                     5% 60                     8%
A08 - Colorectal - Transanal Endoscopic Microsurgery 503                   54% 502                   60%
D10 - Orthopaedic Surgery 1,637               22% 1,462                13%
D10 - Orthopaedic Surgery - revisions 176                   53% 142                   36%
A05 - Morbid Obesity Surgery 8,252               1% 7,908                2%
D12 - Ophthalmology 20,004             2% 19,558             1%
B08 - Haemoglobinopathy - Sickle Cell 13,553             7% 13,064             5%
B08 - Haemoglobinopathy - Thalassaemia 8,651               0% 8,646                3%
Highly Specialised 11,355             74% 10,702             67%
T ota l sample 12,286,246 11,927,415 
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Sensitivity analysis: FCEs rather than spells as unit of observation 
Table 16 provides details of the estimates when the unit of observation is based on FCEs rather than 
spells. Comparison with the estimates presented in Table 15 shows that the cost differences are not 
sensitive to this choice: 
 
x There is little difference in the cost differences for the full sample  W column [a] in Table 15 
and column [c] in Table 16.  For only 6 PSS markers with more than 300 patients is the 
difference more than 10%. 
 
x The same is true for the cost differences for the inlier sample  W column [b] in Table 15 and 
column [d] in Table 16.  For only 7 PSS markers with more than 300 patients is the 
difference more than 10%. 
 
x Unsurprisingly, therefore, conclusions drawn Table 16 are the same as those for Table 15. 
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Table 16 Analyses using FCEs as the unit of observation  
 
 
 
PSS chapter Full sample Full sample Inlier sample Inlier sample
FCEs FCEs FCEs FCEs
n % n %
[c] [d]
B03 - Chemotherapy 47,306             51% 47,115             54%
B02 - PET-CT 4                        486% 2                        223%
B01 - Radiotherapy 7,719                140% 7,057                126%
D05 - Stereotactic Radiosurgery 199                   -194% 195                   -180%
B03 - Teenage and Young Adults Cancer 7,102                32% 6,946                29%
B03 - Rare Cancers (Adult) 35,623             20% 33,791             18%
B04 - BMT 1,893                -6% 1,846                -3%
B05  - Haemophilia 3,689                76% 3,630                75%
E10 - Women - Complex Minimal Access Gynaecology Surgery 1,281                -8% 1,270                -5%
E12 - Women - Fetal Medicine 176                   68% 170                   25%
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 14                     -1% 14                     3%
E11 - Women - Maternal Medicine (complications of pregnancy) 40,810             10% 38,817             6%
D14 - Spinal - Spinal Surgery 6,706                -6% 6,069                -7%
D04 - Neurosciences - Neurology 103,517           58% 98,041             47%
D04 - Neurosciences - Neurophysiology 88                     -46% 88                     -40%
D04 - Neurosciences - Neuroradiology 13                     -43% 13                     -41%
D03 - Neurosciences - Neurosurgery 60,753             43% 56,787             39%
D06 - Burns Care 3,115                73% 2,915                49%
A01 - Cystic fibrosis 741                   25% 732                   30%
A06 - Renal Services - Access for dialysis 14,744             60% 13,300             30%
A07  - Renal Services - Renal Transplantation 9,760                -4% 9,272                -5%
A09 - Cardiac - Cardiac electrophysiology 5,850                0% 5,432                1%
A09 - Cardiac - Inherited heart disorders 5,292                55% 4,668                25%
A10 - Cardiac - Cardiac surgery 29,654             33% 27,596             30%
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 28,470             10% 26,953             10%
A11 - Cardiac - Pulmonary hypertension 3,382                43% 3,180                23%
A10 - Cardiac - Cardiovascular magnetic resonance 8                        65% 3                        48%
A10 - Cardiac - Other 16,214             8% 15,673             9%
A13 - Adult Congenital Heart Disease 4,596                4% 4,474                5%
D07 - Cleft Lip Palate 2,712                17% 2,631                16%
B09 - Immunology 9,775                13% 9,750                16%
B09 - Allergy 1,971                -8% 1,971                -3%
B07 - Infectious Diseases Adult 289                   -23% 278                   -30%
B07 - Infectious Diseases Paeds 259                   40% 248                   4%
A02 - Hepatology & Pancreatic 2,839                5% 2,702                5%
C04 - Mental Health - Gender Dysphoria 161                   31% 160                   37%
E04 - Childrens services - Cancer 26,651             12% 26,234             13%
E05 - Childrens services - Cardiac 11,940             42% 11,212             32%
E03 - Childrens services - Endocrinology 3,678                8% 3,665                15%
E03 - Childrens services - Gastroenterology 66,605             16% 64,426             10%
E03 - Childrens services - Haematology 1,961                31% 1,915                30%
E09 - Childrens services - Neurosciences 10,032             77% 9,397                56%
E03 - Childrens services - Ophthalmology 6,809                4% 6,716                5%
E03 - Childrens services - Renal 10,246             32% 10,031             27%
E03 - Childrens services - Respiratory 7,670                68% 7,282                61%
E03 - Childrens services - Rheumatology 6,503                17% 6,152                13%
E02 - Childrens services - Surgery 48,114             7% 46,318             9%
E03 - Childrens services - Paediatric Pain Management 25                     149% 25                     163%
D11 - Hyperbaric Oxygen Treatment 13                     151% 9                        54%
A03d - Respiratory - Pulmonary vascular services 184                   -45% 168                   -40%
A12 - Respiratory - Complex thoracic surgery 31,004             50% 29,183             52%
A03d - Respiratory - Management of central airway obstruction 2,044                88% 1,889                75%
A03d - Respiratory - Interstitial lung disease 2,837                2% 2,803                7%
A03d - Respiratory - Other 16,843             17% 15,193             2%
A04 - Vascular Services 5,500                10% 5,181                7%
D09 - Ears - Cochlear Implants 1,153                -3% 1,043                0%
D09 - Ears - Bone anchored hearing aids 1,371                1% 1,342                3%
D09 - Ears - Middle Ear Implants 113                   -11% 108                   -9%
A08 - Colorectal - Complex Surgery for Incontinence 1,090                -42% 1,087                -40%
A08 - Colorectal - Complex Inflammatory Bowel disease 64                     8% 61                     11%
A08 - Colorectal - Transanal Endoscopic Microsurgery 505                   58% 504                   65%
D10 - Orthopaedic Surgery 1,664                22% 1,487                15%
D10 - Orthopaedic Surgery - revisions 179                   51% 145                   34%
A05 - Morbid Obesity Surgery 8,330                1% 7,982                2%
D12 - Ophthalmology 20,049             1% 19,599             1%
B08 - Haemoglobinopathy - Sickle Cell 13,788             12% 13,280             10%
B08 - Haemoglobinopathy - Thalassaemia 8,651                0% 8,646                3%
Highly Specialised 12,166             90% 11,452             79%
T ota l sample 14,184,683 13,779,336 
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Sensitivity analysis: Using the PSS toolkit to identify specialised services 
As discussed, because it incorporates various data quality checks, the PSS toolkit identifies fewer 
patients as having received specialised care than we do when we programme the PSS Identification 
Rules based on the designated ICD and OPCS codes.  In Table 17 we report details of analyses based 
on our identification of patients who received PPS care and that subset of patients identified using 
the PSS toolkit.  The main points are: 
 
x For the majority of PSS markers, the volume of patients identified by both methods is very 
similar (our approach always identifies more). Unsurprisingly, therefore, the cost 
differences are virtually identical in most instances; 
 
x For only six of the PSS markers the cost differences differ by more than 0.1 (ie 10%).  For 
four of these, the markers apply to fewer than 200 patients.  For the other two (D06-Burns 
Care and E03-Childrens services-Renal), we are identifying substantially more patients than 
the toolkit does.    
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Table 17 Analyses in which PSS specialised is identified using the PSS toolkit 
 
  
PSS chapter Full sample Full sample Full sample Full sample
FCEs FCEs FCEs toolkit FCEs toolkit
n % n %
[c] [e]
B03 - Chemotherapy 47,306             51% 47,003             49%
B02 - PET-CT 4                        486% -                    N/A
B01 - Radiotherapy 7,719                140% 6,963                140%
D05 - Stereotactic Radiosurgery 199                   -194% 196                   -146%
B03 - Teenage and Young Adults Cancer 7,102                32% 7,017                32%
B03 - Rare Cancers (Adult) 35,623             20% 35,097             23%
B04 - BMT 1,893                -6% 1,845                -14%
B05  - Haemophilia 3,689                76% 3,003                83%
E10 - Women - Complex Minimal Access Gynaecology Surgery 1,281                -8% 977                   -11%
E12 - Women - Fetal Medicine 176                   68% 175                   69%
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 14                     -1% 10                     2%
E11 - Women - Maternal Medicine (complications of pregnancy) 40,810             10% 40,266             11%
D14 - Spinal - Spinal Surgery 6,706                -6% 5,772                -8%
D04 - Neurosciences - Neurology 103,517           58% 102,386           50%
D04 - Neurosciences - Neurophysiology 88                     -46% 88                     -47%
D04 - Neurosciences - Neuroradiology 13                     -43% 12                     -39%
D03 - Neurosciences - Neurosurgery 60,753             43% 53,301             41%
D06 - Burns Care 3,115                73% 2,397                25%
A01 - Cystic fibrosis 741                   25% 699                   30%
A06 - Renal Services - Access for dialysis 14,744             60% 10,171             60%
A07  - Renal Services - Renal Transplantation 9,760                -4% 8,558                -3%
A09 - Cardiac - Cardiac electrophysiology 5,850                0% 5,828                1%
A09 - Cardiac - Inherited heart disorders 5,292                55% 5,258                55%
A10 - Cardiac - Cardiac surgery 29,654             33% 27,549             32%
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 28,470             10% 25,523             11%
A11 - Cardiac - Pulmonary hypertension 3,382                43% 3,336                41%
A10 - Cardiac - Cardiovascular magnetic resonance 8                        65% -                    N/A
A10 - Cardiac - Other 16,214             8% 16,023             7%
A13 - Adult Congenital Heart Disease 4,596                4% 4,559                5%
D07 - Cleft Lip Palate 2,712                17% 1,949                -7%
B09 - Immunology 9,775                13% 9,747                12%
B09 - Allergy 1,971                -8% 1,971                -12%
B07 - Infectious Diseases Adult 289                   -23% 273                   -24%
B07 - Infectious Diseases Paeds 259                   40% 252                   33%
A02 - Hepatology & Pancreatic 2,839                5% 2,727                7%
C04 - Mental Health - Gender Dysphoria 161                   31% 161                   33%
E04 - Childrens services - Cancer 26,651             12% 26,403             13%
E05 - Childrens services - Cardiac 11,940             42% 11,885             28%
E03 - Childrens services - Endocrinology 3,678                8% 3,610                8%
E03 - Childrens services - Gastroenterology 66,605             16% 65,782             14%
E03 - Childrens services - Haematology 1,961                31% 1,941                31%
E09 - Childrens services - Neurosciences 10,032             77% 9,726                69%
E03 - Childrens services - Ophthalmology 6,809                4% 6,779                3%
E03 - Childrens services - Renal 10,246             32% 6,512                35%
E03 - Childrens services - Respiratory 7,670                68% 7,522                68%
E03 - Childrens services - Rheumatology 6,503                17% 5,929                12%
E02 - Childrens services - Surgery 48,114             7% 60,410             29%
E03 - Childrens services - Paediatric Pain Management 25                     149% 23                     135%
D11 - Hyperbaric Oxygen Treatment 13                     151% 12                     152%
A03d - Respiratory - Pulmonary vascular services 184                   -45% 183                   1%
A12 - Respiratory - Complex thoracic surgery 31,004             50% 30,404             52%
A03d - Respiratory - Management of central airway obstruction 2,044                88% 1,990                88%
A03d - Respiratory - Interstitial lung disease 2,837                2% 2,755                4%
A03d - Respiratory - Other 16,843             17% 15,923             16%
A04 - Vascular Services 5,500                10% 5,434                12%
D09 - Ears - Cochlear Implants 1,153                -3% 1,145                -14%
D09 - Ears - Bone anchored hearing aids 1,371                1% 1,363                -1%
D09 - Ears - Middle Ear Implants 113                   -11% 113                   -11%
A08 - Colorectal - Complex Surgery for Incontinence 1,090                -42% 1,083                -43%
A08 - Colorectal - Complex Inflammatory Bowel disease 64                     8% 64                     12%
A08 - Colorectal - Transanal Endoscopic Microsurgery 505                   58% 503                   60%
D10 - Orthopaedic Surgery 1,664                22% 1,632                33%
D10 - Orthopaedic Surgery - revisions 179                   51% 127                   39%
A05 - Morbid Obesity Surgery 8,330                1% 8,303                2%
D12 - Ophthalmology 20,049             1% 19,968             3%
B08 - Haemoglobinopathy - Sickle Cell 13,788             12% 13,639             11%
B08 - Haemoglobinopathy - Thalassaemia 8,651                0% 8,639                0%
Highly Specialised 12,166             90% -                    N/A
T ota l sample 14,184,683 14,184,683 
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Sensitivity analysis: Dropping HRGs in which everyone or no-one received specialised services 
There are 42 HRGs in which everybody is identified as having received specialised care as defined by 
the PSS.  At the other extreme, there are 36 HRGs in which nobody received specialised care.  For 
these HRGs, there is no need to pay a top-up for specialised care, either because the costs will be 
embodied in the base HRG payment or because specialised care is irrelevant. 
 
If patients allocated to these HRGs are omitted, 41,829 spells are dropped from the analytical 
sample.  The impact that this has on the results is reported in Table 18.  None of the PSS markers are 
sensitive to omitting these patients from the analysis. 
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Table 18 Sensitivity analysis to omission of fully or non-specialised HRGs 
 
 
  
PSS chapter Full sample Full sample Drop 100% & 0% Drop 100% & 0%
Spells Spells Spells Spells
n % n %
[a] [f]
B03 - Chemotherapy 47,186             50% 47,033                      50%
B02 - PET-CT 4                       483% 4                                484%
B01 - Radiotherapy 7,363               129% 7,306                        130%
D05 - Stereotactic Radiosurgery 192                   -182% 191                            -183%
B03 - Teenage and Young Adults Cancer 6,829               31% 6,790                        31%
B03 - Rare Cancers (Adult) 29,364             22% 29,357                      22%
B04 - BMT 1,846               -5% 2                                430%
B05  - Haemophilia 3,559               80% 3,558                        80%
E10 - Women - Complex Minimal Access Gynaecology Surgery 1,274               -8% 1,274                        -8%
E12 - Women - Fetal Medicine 168                   0% 168                            0%
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 14                     83% 14                              83%
E11 - Women - Maternal Medicine (complications of pregnancy) 39,629             11% 39,628                      11%
D14 - Spinal - Spinal Surgery 6,333               -1% 6,332                        -1%
D04 - Neurosciences - Neurology 96,650             43% 96,649                      43%
D04 - Neurosciences - Neurophysiology 87                     -34% 87                              -34%
D04 - Neurosciences - Neuroradiology 13                     -43% 13                              -43%
D03 - Neurosciences - Neurosurgery 54,455             41% 54,453                      41%
D06 - Burns Care 2,948               71% 2,948                        71%
A01 - Cystic fibrosis 646                   25% 642                            26%
A06 - Renal Services - Access for dialysis 13,323             59% 13,323                      59%
A07  - Renal Services - Renal Transplantation 9,296               -1% 9,295                        -1%
A09 - Cardiac - Cardiac electrophysiology 5,671               1% 5,671                        1%
A09 - Cardiac - Inherited heart disorders 3,955               53% 3,955                        53%
A10 - Cardiac - Cardiac surgery 24,744             24% 24,599                      24%
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 25,910             25% 25,907                      25%
A11 - Cardiac - Pulmonary hypertension 3,292               29% 3,292                        29%
A10 - Cardiac - Cardiovascular magnetic resonance 8                       52% 7                                71%
A10 - Cardiac - Other 15,791             5% 15,790                      5%
A13 - Adult Congenital Heart Disease 4,185               6% 3,988                        10%
D07 - Cleft Lip Palate 2,695               10% 2,694                        9%
B09 - Immunology 9,760               12% 9,757                        12%
B09 - Allergy 1,971               -13% 1,971                        -13%
B07 - Infectious Diseases Adult 268                   -38% 268                            -38%
B07 - Infectious Diseases Paeds 247                   33% 244                            33%
A02 - Hepatology & Pancreatic 2,342               8% 2,342                        8%
C04 - Mental Health - Gender Dysphoria 160                   30% 160                            30%
E04 - Childrens services - Cancer 25,405             12% 24,205                      14%
E05 - Childrens services - Cardiac 8,645               44% 8,109                        46%
E03 - Childrens services - Endocrinology 3,671               8% 3,671                        8%
E03 - Childrens services - Gastroenterology 62,385             16% 60,889                      17%
E03 - Childrens services - Haematology 1,919               32% 1,907                        32%
E09 - Childrens services - Neurosciences 9,071               73% 9,060                        72%
E03 - Childrens services - Ophthalmology 6,725               4% 5,942                        6%
E03 - Childrens services - Renal 9,593               31% 9,548                        31%
E03 - Childrens services - Respiratory 7,184               73% 7,182                        73%
E03 - Childrens services - Rheumatology 6,047               11% 6,041                        10%
E02 - Childrens services - Surgery 44,589             13% 41,547                      14%
E03 - Childrens services - Paediatric Pain Management 25                     150% 25                              150%
D11 - Hyperbaric Oxygen Treatment 12                     139% 12                              139%
A03d - Respiratory - Pulmonary vascular services 178                   -32% 178                            -35%
A12 - Respiratory - Complex thoracic surgery 27,615             43% 27,546                      43%
A03d - Respiratory - Management of central airway obstruction 1,901               68% 1,899                        68%
A03d - Respiratory - Interstitial lung disease 2,534               -10% 2,534                        -10%
A03d - Respiratory - Other 13,953             22% 13,941                      22%
A04 - Vascular Services 4,839               17% 4,835                        17%
D09 - Ears - Cochlear Implants 1,150               -6% 61                              -14%
D09 - Ears - Bone anchored hearing aids 1,370               0% 30                              1%
D09 - Ears - Middle Ear Implants 113                   -12% 112                            -12%
A08 - Colorectal - Complex Surgery for Incontinence 1,090               -42% 1,090                        -42%
A08 - Colorectal - Complex Inflammatory Bowel disease 63                     5% 63                              5%
A08 - Colorectal - Transanal Endoscopic Microsurgery 503                   54% 503                            54%
D10 - Orthopaedic Surgery 1,637               22% 1,637                        21%
D10 - Orthopaedic Surgery - revisions 176                   53% 176                            53%
A05 - Morbid Obesity Surgery 8,252               1% 4,112                        0%
D12 - Ophthalmology 20,004             2% 20,003                      2%
B08 - Haemoglobinopathy - Sickle Cell 13,553             7% 13,551                      6%
B08 - Haemoglobinopathy - Thalassaemia 8,651               0% 8,651                        0%
Highly Specialised 11,355             74% 11,131                      76%
T ota l sample 12,286,246 12,244,417       
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Sensitivity analysis: dropping eligibility requirements  
In this sensitivity analysis we relax the condition that the patient had to be treated at an eligible 
provider in order to be identified as having received some form of specialised care.  With the 
relaxation of this condition, identification is conditional only on the presence of the relevant 
identification rules ŝŶƚŚĞƉĂƚŝĞŶƚ ?Ɛ,^ƌĞĐŽƌĚ ? 
 
Relaxation of the eligibility requirement increases the number of patients identified as having 
received specialised care, but only for the following PSS markers and for some of these, there is only 
a small increase in numbers identified: 
 
x B05  - Haemophilia 
x D14 - Spinal - Spinal Surgery 
x D03 - Neurosciences - Neurosurgery 
x A01 - Cystic fibrosis 
x A10 - Cardiac - Cardiac surgery 
x A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 
x A11 - Cardiac - Pulmonary hypertension 
x D07 - Cleft Lip Palate 
x B07 - Infectious Diseases Adult 
x A03d - Respiratory - Interstitial lung disease 
  
We might expect, then, that results for these PSS markers are sensitive to relaxation of the eligibility 
condition, while those for other markers are unchanged.  As Table 19 shows, there is indeed no 
change for the markers unaffected by relaxing of the eligibility requirement.  For the above markers 
in which changes might be expected, there is no uniformity in the size or direction of change.  
 
Following relaxation of the eligibility condition, the percentage effect increases for the following PSS 
markers: 
 
x A10 - Cardiac - Cardiac surgery from 24% to 28% 
x A11 - Cardiac - Pulmonary hypertension from 29% to 36% 
x B07 - Infectious Diseases Adult (though the effect on this marker is negative) 
 
In contrast, the percentage effect falls for B05 - Haemophilia and there is no change for the other 
PSS markers. 
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Table 19 Sensitivity to dropping eligibility requirements in identifying specialised care 
 
 
 
  
PSS chapter Full sample Full sample Eligibility Eligibility
Spells Spells Spells Spells Increase in
n % n % n
[a] [g]
B03 - Chemotherapy 47,186             50% 47,186             50% -                    
B02 - PET-CT 4                       483% 4                        484% -                    
B01 - Radiotherapy 7,363               129% 7,363                129% -                    
D05 - Stereotactic Radiosurgery 192                   -182% 192                   -183% -                    
B03 - Teenage and Young Adults Cancer 6,829               31% 6,829                31% -                    
B03 - Rare Cancers (Adult) 29,364             22% 29,364             22% -                    
B04 - BMT 1,846               -5% 1,846                -5% -                    
B05  - Haemophilia 3,559               80% 5,264                48% 1,705                
E10 - Women - Complex Minimal Access Gynaecology Surgery 1,274               -8% 1,274                -8% -                    
E12 - Women - Fetal Medicine 168                   0% 168                   1% -                    
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 14                     83% 14                     83% -                    
E11 - Women - Maternal Medicine (complications of pregnancy) 39,629             11% 39,629             11% -                    
D14 - Spinal - Spinal Surgery 6,333               -1% 9,221                -5% 2,888                
D04 - Neurosciences - Neurology 96,650             43% 96,650             43% -                    
D04 - Neurosciences - Neurophysiology 87                     -34% 87                     -34% -                    
D04 - Neurosciences - Neuroradiology 13                     -43% 13                     -43% -                    
D03 - Neurosciences - Neurosurgery 54,455             41% 56,095             42% 1,640                
D06 - Burns Care 2,948               71% 2,948                71% -                    
A01 - Cystic fibrosis 646                   25% 747                   24% 101                   
A06 - Renal Services - Access for dialysis 13,323             59% 13,323             59% -                    
A07  - Renal Services - Renal Transplantation 9,296               -1% 9,296                -1% -                    
A09 - Cardiac - Cardiac electrophysiology 5,671               1% 5,671                1% -                    
A09 - Cardiac - Inherited heart disorders 3,955               53% 3,955                53% -                    
A10 - Cardiac - Cardiac surgery 24,744             24% 27,418             28% 2,674                
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 25,910             25% 30,563             25% 4,653                
A11 - Cardiac - Pulmonary hypertension 3,292               29% 4,389                36% 1,097                
A10 - Cardiac - Cardiovascular magnetic resonance 8                       52% 8                        52% -                    
A10 - Cardiac - Other 15,791             5% 15,791             4% -                    
A13 - Adult Congenital Heart Disease 4,185               6% 4,185                6% -                    
D07 - Cleft Lip Palate 2,695               10% 2,811                11% 116                   
B09 - Immunology 9,760               12% 9,760                12% -                    
B09 - Allergy 1,971               -13% 1,971                -13% -                    
B07 - Infectious Diseases Adult 268                   -38% 279                   -26% 11                     
B07 - Infectious Diseases Paeds 247                   33% 247                   33% -                    
A02 - Hepatology & Pancreatic 2,342               8% 2,342                8% -                    
C04 - Mental Health - Gender Dysphoria 160                   30% 160                   30% -                    
E04 - Childrens services - Cancer 25,405             12% 25,405             13% -                    
E05 - Childrens services - Cardiac 8,645               44% 8,645                44% -                    
E03 - Childrens services - Endocrinology 3,671               8% 3,671                8% -                    
E03 - Childrens services - Gastroenterology 62,385             16% 62,385             16% -                    
E03 - Childrens services - Haematology 1,919               32% 1,919                32% -                    
E09 - Childrens services - Neurosciences 9,071               73% 9,071                73% -                    
E03 - Childrens services - Ophthalmology 6,725               4% 6,725                3% -                    
E03 - Childrens services - Renal 9,593               31% 9,593                31% -                    
E03 - Childrens services - Respiratory 7,184               73% 7,184                73% -                    
E03 - Childrens services - Rheumatology 6,047               11% 6,047                11% -                    
E02 - Childrens services - Surgery 44,589             13% 44,589             13% -                    
E03 - Childrens services - Paediatric Pain Management 25                     150% 25                     150% -                    
D11 - Hyperbaric Oxygen Treatment 12                     139% 12                     139% -                    
A03d - Respiratory - Pulmonary vascular services 178                   -32% 178                   -35% -                    
A12 - Respiratory - Complex thoracic surgery 27,615             43% 27,615             39% -                    
A03d - Respiratory - Management of central airway obstruction 1,901               68% 1,901                69% -                    
A03d - Respiratory - Interstitial lung disease 2,534               -10% 8,285                1% 5,751                
A03d - Respiratory - Other 13,953             22% 13,953             22% -                    
A04 - Vascular Services 4,839               17% 4,839                17% -                    
D09 - Ears - Cochlear Implants 1,150               -6% 1,150                -6% -                    
D09 - Ears - Bone anchored hearing aids 1,370               0% 1,370                0% -                    
D09 - Ears - Middle Ear Implants 113                   -12% 113                   -12% -                    
A08 - Colorectal - Complex Surgery for Incontinence 1,090               -42% 1,090                -42% -                    
A08 - Colorectal - Complex Inflammatory Bowel disease 63                     5% 63                     5% -                    
A08 - Colorectal - Transanal Endoscopic Microsurgery 503                   54% 503                   54% -                    
D10 - Orthopaedic Surgery 1,637               22% 1,637                22% -                    
D10 - Orthopaedic Surgery - revisions 176                   53% 176                   53% -                    
A05 - Morbid Obesity Surgery 8,252               1% 8,252                1% -                    
D12 - Ophthalmology 20,004             2% 20,004             2% -                    
B08 - Haemoglobinopathy - Sickle Cell 13,553             7% 13,553             7% -                    
B08 - Haemoglobinopathy - Thalassaemia 8,651               0% 8,651                0% -                    
Highly Specialised 11,355             74% 11,355             74% -                    
T ota l sample 12,286,246 12,286,246 
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Sensitivity analysis: including those with partially matched costs  
In Table 20 we expand the analytical sample to include those with partially matched Reference 
Costs.  This increases the number of FCEs in the analysis from 14,184,683 to 15,234,491.  This 
changes some of the percentage effects, but rarely by more than 3%.   Where changes are larger 
than this, these occur for those PSS markers with relatively small numbers of patients. 
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Table 20 Inclusion of patients with partially matched costs 
 
  
PSS chapter Full sample Full sample Imperfect match Imperfect match
Spells Spells FCEs FCEs
n % n %
[a] [h]
B03 - Chemotherapy 47,186             50% 50,772                    49%
B02 - PET-CT 4                       483% 5                              392%
B01 - Radiotherapy 7,363               129% 8,244                      134%
D05 - Stereotactic Radiosurgery 192                   -182% 233                          -183%
B03 - Teenage and Young Adults Cancer 6,829               31% 7,771                      29%
B03 - Rare Cancers (Adult) 29,364             22% 40,941                    20%
B04 - BMT 1,846               -5% 2,313                      -5%
B05  - Haemophilia 3,559               80% 4,041                      70%
E10 - Women - Complex Minimal Access Gynaecology Surgery 1,274               -8% 1,282                      -8%
E12 - Women - Fetal Medicine 168                   0% 179                          65%
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 14                     83% 15                            2%
E11 - Women - Maternal Medicine (complications of pregnancy) 39,629             11% 44,057                    10%
D14 - Spinal - Spinal Surgery 6,333               -1% 7,260                      -5%
D04 - Neurosciences - Neurology 96,650             43% 109,244                  52%
D04 - Neurosciences - Neurophysiology 87                     -34% 148                          9%
D04 - Neurosciences - Neuroradiology 13                     -43% 31                            -22%
D03 - Neurosciences - Neurosurgery 54,455             41% 63,160                    40%
D06 - Burns Care 2,948               71% 5,756                      51%
A01 - Cystic fibrosis 646                   25% 1,058                      21%
A06 - Renal Services - Access for dialysis 13,323             59% 15,648                    58%
A07  - Renal Services - Renal Transplantation 9,296               -1% 10,335                    -3%
A09 - Cardiac - Cardiac electrophysiology 5,671               1% 5,914                      0%
A09 - Cardiac - Inherited heart disorders 3,955               53% 5,605                      57%
A10 - Cardiac - Cardiac surgery 24,744             24% 35,514                    31%
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 25,910             25% 28,990                    10%
A11 - Cardiac - Pulmonary hypertension 3,292               29% 3,401                      40%
A10 - Cardiac - Cardiovascular magnetic resonance 8                       52% 8                              66%
A10 - Cardiac - Other 15,791             5% 17,539                    6%
A13 - Adult Congenital Heart Disease 4,185               6% 4,950                      4%
D07 - Cleft Lip Palate 2,695               10% 2,836                      17%
B09 - Immunology 9,760               12% 10,658                    13%
B09 - Allergy 1,971               -13% 2,538                      5%
B07 - Infectious Diseases Adult 268                   -38% 301                          -21%
B07 - Infectious Diseases Paeds 247                   33% 274                          40%
A02 - Hepatology & Pancreatic 2,342               8% 3,519                      5%
C04 - Mental Health - Gender Dysphoria 160                   30% 162                          31%
E04 - Childrens services - Cancer 25,405             12% 28,587                    11%
E05 - Childrens services - Cardiac 8,645               44% 14,509                    41%
E03 - Childrens services - Endocrinology 3,671               8% 3,780                      6%
E03 - Childrens services - Gastroenterology 62,385             16% 72,978                    17%
E03 - Childrens services - Haematology 1,919               32% 2,171                      27%
E09 - Childrens services - Neurosciences 9,071               73% 11,154                    73%
E03 - Childrens services - Ophthalmology 6,725               4% 7,141                      7%
E03 - Childrens services - Renal 9,593               31% 12,261                    30%
E03 - Childrens services - Respiratory 7,184               73% 8,531                      68%
E03 - Childrens services - Rheumatology 6,047               11% 7,871                      18%
E02 - Childrens services - Surgery 44,589             13% 54,878                    7%
E03 - Childrens services - Paediatric Pain Management 25                     150% 25                            145%
D11 - Hyperbaric Oxygen Treatment 12                     139% 16                            120%
A03d - Respiratory - Pulmonary vascular services 178                   -32% 197                          -38%
A12 - Respiratory - Complex thoracic surgery 27,615             43% 38,667                    43%
A03d - Respiratory - Management of central airway obstruction 1,901               68% 2,667                      74%
A03d - Respiratory - Interstitial lung disease 2,534               -10% 3,039                      2%
A03d - Respiratory - Other 13,953             22% 21,007                    16%
A04 - Vascular Services 4,839               17% 6,346                      9%
D09 - Ears - Cochlear Implants 1,150               -6% 1,231                      -3%
D09 - Ears - Bone anchored hearing aids 1,370               0% 1,380                      1%
D09 - Ears - Middle Ear Implants 113                   -12% 115                          -11%
A08 - Colorectal - Complex Surgery for Incontinence 1,090               -42% 1,691                      -50%
A08 - Colorectal - Complex Inflammatory Bowel disease 63                     5% 84                            11%
A08 - Colorectal - Transanal Endoscopic Microsurgery 503                   54% 529                          55%
D10 - Orthopaedic Surgery 1,637               22% 1,724                      22%
D10 - Orthopaedic Surgery - revisions 176                   53% 184                          49%
A05 - Morbid Obesity Surgery 8,252               1% 8,431                      0%
D12 - Ophthalmology 20,004             2% 20,233                    1%
B08 - Haemoglobinopathy - Sickle Cell 13,553             7% 13,902                    15%
B08 - Haemoglobinopathy - Thalassaemia 8,651               0% 8,848                      1%
Highly Specialised 11,355             74% 13,528                    92%
T ota l sample 12,286,246 15,234,491      
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Accounting for hospital effects 
Table 21 compares equation 1, estimated using OLS, with equation 2, which accounts for hospital 
clustering using a random effects specification.  The table provides estimates of the cost differences 
between these specifications. 
 
As we found for the SSNDS markers, the cost differences are invariably larger for the OLS model than 
the RE model that accounts for clustering, for the same reasons as previously. 
 
For 28 PSS markers, the cost differential between those that do and do not receive specialised care 
is more than 10% for 28 PSS markers; for 16 of these the difference is more than 25%; and for 7 it is 
more than 50%. 
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 Table 21 Comparison of OLS and RE models 
 
  
PSS chapter Full sample Full sample Full sample
Spells Spells Spells RE
n % %
[a] [i]
B03 - Chemotherapy 47,186             50% 49%
B02 - PET-CT 4                       483% 451%
B01 - Radiotherapy 7,363               129% 113%
D05 - Stereotactic Radiosurgery 192                   -182% -172%
B03 - Teenage and Young Adults Cancer 6,829               31% 25%
B03 - Rare Cancers (Adult) 29,364             22% 19%
B04 - BMT 1,846               -5% -10%
B05  - Haemophilia 3,559               80% 65%
E10 - Women - Complex Minimal Access Gynaecology Surgery 1,274               -8% -7%
E12 - Women - Fetal Medicine 168                   0% -5%
E10 - Women - Complex Urinary and Faecal Incontinence & Genital Prolapse 14                     83% 77%
E11 - Women - Maternal Medicine (complications of pregnancy) 39,629             11% 10%
D14 - Spinal - Spinal Surgery 6,333               -1% -3%
D04 - Neurosciences - Neurology 96,650             43% 39%
D04 - Neurosciences - Neurophysiology 87                     -34% -33%
D04 - Neurosciences - Neuroradiology 13                     -43% -53%
D03 - Neurosciences - Neurosurgery 54,455             41% 36%
D06 - Burns Care 2,948               71% 62%
A01 - Cystic fibrosis 646                   25% 9%
A06 - Renal Services - Access for dialysis 13,323             59% 52%
A07  - Renal Services - Renal Transplantation 9,296               -1% -5%
A09 - Cardiac - Cardiac electrophysiology 5,671               1% -7%
A09 - Cardiac - Inherited heart disorders 3,955               53% 48%
A10 - Cardiac - Cardiac surgery 24,744             24% 21%
A09 - Cardiac - PPCI and Structural Heart Disease (Complex Invasive Cardiology) 25,910             25% 22%
A11 - Cardiac - Pulmonary hypertension 3,292               29% 18%
A10 - Cardiac - Cardiovascular magnetic resonance 8                       52% 53%
A10 - Cardiac - Other 15,791             5% 2%
A13 - Adult Congenital Heart Disease 4,185               6% 1%
D07 - Cleft Lip Palate 2,695               10% 0%
B09 - Immunology 9,760               12% 8%
B09 - Allergy 1,971               -13% -11%
B07 - Infectious Diseases Adult 268                   -38% -36%
B07 - Infectious Diseases Paeds 247                   33% 27%
A02 - Hepatology & Pancreatic 2,342               8% 2%
C04 - Mental Health - Gender Dysphoria 160                   30% 37%
E04 - Childrens services - Cancer 25,405             12% 7%
E05 - Childrens services - Cardiac 8,645               44% 29%
E03 - Childrens services - Endocrinology 3,671               8% -11%
E03 - Childrens services - Gastroenterology 62,385             16% 10%
E03 - Childrens services - Haematology 1,919               32% 19%
E09 - Childrens services - Neurosciences 9,071               73% 52%
E03 - Childrens services - Ophthalmology 6,725               4% -1%
E03 - Childrens services - Renal 9,593               31% 12%
E03 - Childrens services - Respiratory 7,184               73% 50%
E03 - Childrens services - Rheumatology 6,047               11% 2%
E02 - Childrens services - Surgery 44,589             13% 4%
E03 - Childrens services - Paediatric Pain Management 25                     150% 145%
D11 - Hyperbaric Oxygen Treatment 12                     139% 140%
A03d - Respiratory - Pulmonary vascular services 178                   -32% -22%
A12 - Respiratory - Complex thoracic surgery 27,615             43% 37%
A03d - Respiratory - Management of central airway obstruction 1,901               68% 59%
A03d - Respiratory - Interstitial lung disease 2,534               -10% -39%
A03d - Respiratory - Other 13,953             22% 19%
A04 - Vascular Services 4,839               17% 15%
D09 - Ears - Cochlear Implants 1,150               -6% -9%
D09 - Ears - Bone anchored hearing aids 1,370               0% -5%
D09 - Ears - Middle Ear Implants 113                   -12% -17%
A08 - Colorectal - Complex Surgery for Incontinence 1,090               -42% -45%
A08 - Colorectal - Complex Inflammatory Bowel disease 63                     5% 4%
A08 - Colorectal - Transanal Endoscopic Microsurgery 503                   54% 49%
D10 - Orthopaedic Surgery 1,637               22% 15%
D10 - Orthopaedic Surgery - revisions 176                   53% 45%
A05 - Morbid Obesity Surgery 8,252               1% 1%
D12 - Ophthalmology 20,004             2% 2%
B08 - Haemoglobinopathy - Sickle Cell 13,553             7% 0%
B08 - Haemoglobinopathy - Thalassaemia 8,651               0% -8%
Highly Specialised 11,355             74% 57%
T ota l sample 12,286,246 
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6. Conclusion 
This report updates our previous analyses estimating the costs associated with specialised care.  In 
the intervening period the rules used to identify whether or not a patient has received specialised 
care have been overhauled.  Although fundamental principles remain the same, the new Prescribed 
Specialised Services (PSS) system represents a radical departure from the superseded Specialised 
Services National Definition Sets (SSNDS).  
 
We have applied both sets of rules to the 18,754,381 FCEs in the 2011/12 Hospital Episode Statistics 
(HES).  Of these, 2,183,702 (11.6%) are identified as having received specialised care according to the 
SSNDS, compared to only 1,611,552 (8.6%) under PSS rules.  There is little overlap between the 
SSNDS and PSS: of all those identified as having received specialised care under the two systems, 
only 537,324 (16.5%) are identified under both. Of the 69 PSS markers that apply to hospital care, 11 
apply to fewer than 300 patients nationally. 
 
We analyse costs for each individual patient to determine whether the receipt of specialised care is 
associated with higher costs relative to patients allocated to the same HRG who did not receive 
specialised care. To do this, we have matched HES records to Reference Costs (RC) reported by each 
NHS hospital.  Our analytical sample comprises 12,286,246 spells (14,184,683 FCEs) of which 10% are 
designated as having received specialised care according to the SSNDS system and 5.4% according to 
the PSS system. 
 
Two broad sets of analyses are conducted, according to whether the SSNDS or PSS is used to identify 
receipt of specialised care.  We conduct various sensitivity analyses, including the use of FCEs rather 
than spells as the unit of observation; restriction of the sample to inliers, those who did not stay 
beyond their HRG-specific length of stay trimpoint; and to those who were not allocated to fully 
specialised or non-specialised HRGs; and to relaxing the identification requirement for specialised 
care that patients have to be treated at eligible providers. 
 
For the SSNDS markers, we compare previous results for 2009/10 with those for 2011/12.  As well as 
a different population, there will have been changes over time to clinical, coding and costing practice 
and to the HRG casemix classification.  Results for 13 of the 27 of the markers are very similar 
between the two years.  For the remainder, the markers are either now statistically significant (8 of 
27) or the cost differentials have changed substantially (6 of 27).  With the exception of 
Neurosciences, there have also been marked changes in volume of patients receiving these types of 
specialised care.  
 
Most of the PSS markers are positive and significant, implying that patients who received specialised 
care of the type indicated had higher costs than other patients allocated to the same HRG.  For some 
PSS markers the financial implications of the cost differences will be small, partly because only small 
volumes of patients received the specialised care in question or because the cost differences are 
small.  The cost differential between those that do and do not receive specialised care is more than 
10% for 28 PSS markers; for 16 of these the difference is more than 25%; and for 7 it is more than 
50%. 
 
The estimated cost differentials are robust to the various sensitivity analyses that we conduct for 
both the PSS and SSNDS markers.  Fewer patients are identified as having received specialised care 
under the PSS system than the SSNDS.  But the percentage cost differences tend to be larger for the 
PSS markers than for the SSNDS markers.  The implication is that, although the PSS system is 
identifying fewer patients, because the cost differentials are larger, identification of those that 
receive specialised care appears more precise under the PSS than the SSNDS. 
The costs of specialised care  41 
 
 
We recommend that, if top-up arrangements are to be made, the following should be considered: 
 
x The top-up differential should be based on results from the RE model that takes account of 
hospital effects in calculating differential costs between those who did and did not receive 
specialised care; 
 
x Top-up payments should be applied only to those PSS markers for which the financial 
implications are likely to prove material. Materiality should be based on both the expected 
volume of patients to whom they are to apply and on the size of the estimated cost 
differential. 
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Tony Whitfield ŝƌĞĐƚŽƌŽĨ&ŝŶĂŶĐĞ ?^ƚ:ĂŵĞƐ ?ƐhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂůƐ 
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A2: Technical Working Party data issue decisions (15/06/14)  
 
1. The majority of 43 APC PSS definitions that use OPCS codes in the identification rules, do so via a 
triggering OPCS code in any operation field in the HES data.  There are, however, 3 definitions 
that use the OPCS code in DGVP (Dominant Grouping Variable-Procedure) only.  They are: 
 
PSS ToolKit FCEs CHE FCEs 
NCBPS23X E02 - Paeds Surgery Childrens services - Surgery 110,942 64,466 
NCBPS34A D10 - Orthopaedics Orthopaedic Surgery  1,953 2,007 
NCBPS34R D10 - Orthopaedics Orthopaedic Surgery - revisions 133 188 
 
The DGVP does not come directly from HES but is instead an output of the HRG grouper which via a 
set of rules identifies the dominant OPCS code from a potential list of several in terms of which is 
most influential in determining the HRG. 
 
The supporting information given in the identification rules worksheet for each of the above 
specialised services is sometimes a little ambiguous in definition.  For example, for NCBPS23X, the 
ƐƵƉƉŽƌƚŝŶŐŝŶĨŽƌŵĂƚŝŽŶĚŝƐĐƵƐƐĞƐ ‘ƉƌŝŵĂƌǇƉƌŽĐĞĚƵƌĞƉŽƐŝƚŝŽŶ ?ƌĂƚŚĞƌƚŚĂŶ DGVP per se.  NCBPS34A 
ĂŶĚEW^ ? ?ZƐƚĂƚĞ ‘ĚŽŵŝŶĂŶƚƉƌŽĐĞĚƵƌĞƉŽƐŝƚŝŽŶ ? ? The interpretation of these rules was to check 
the DGVP provided by the 11/12 grouper for any of the triggering OPCS codes.   However as 
indicated in the table above this leads to a situation where there are far fewer PSS CHE identified 
FCEs for  ‘Children ?s Services  W Surgery ? than identified by the PSS toolkit.  For the two orthopaedic 
codes the problem is less pronounced: the PSS CHE tool using the DGVP field identifies a greater 
number of FCEs than the PSS toolkit.  However for Orthopaedic Surgery there are 112 cases where 
the PSS toolkit identifies the FCE as specialised whereas the PSS CHE version does not.   
 
A potential solution explored was to change the identifying rule to check the first operation field in 
HES rather than the grouper provided DGVP. This provides a closer match between PSS CHE and PSS 
toolkit. For example, with Children ?s surgery, this version of the rule identifies 129,993 FCEs as 
having that specialisation.  This 17% increase above that identified by the PSS toolkit is more in 
keeping with general increased number of PSS CHE identified specialised services.   
 
In discussion with the project technical working party, it was felt that the most likely candidate for 
the discrepancy between the original PSS CHE and the PSS toolkit was due to differences in the 
manner in which  the 2012/13 grouper implementation (inherent in the toolkit) and the 2011/12 
grouper identifies the DGVP.  Nevertheless, the technical working party favoured the PSS CHE 
interpretation of the Identification Rules, which uses the DGVP, producing a lower count of services 
for Children ?s surgery.  
 
2. The PSS CHE version of the IR workbook rules has consistently identified more FCEs with PSS 
Toolkit and more PSS services (allowing for more than 1 PSS to be identified per FCE) than the 
PSS toolkit.  Excluding Children ?s Surgery (for reasons outlined above), the PSS CHE version 
identifies approximately 99,000 (or 6%) more PSS services over the full data set than the PSS 
toolkit. 
 
Further investigation shows that approximately 18,500 of these cases are due to the Highly 
Specialised service identified by purchaser code which does not seem to be implemented in the PSS 
toolkit.   
 
The costs of specialised care  45 
 
 
dŚĞƌĞŵĂŝŶŝŶŐ ‘ĞǆĐĞƐƐ ?ƐĞƌǀŝĐĞƐĂƉƉĞĂƌƚŽďĞĂĨƵŶĐƚŝŽŶŽĨ ƚŚĞĚĂƚĂƋƵĂůŝƚǇĐŚĞĐŬƐŝŶŚĞƌĞŶƚŝŶƚŚĞPSS 
toolkit some of which are potentially not applicable to 2011/12 data mainly due to an ICD10 update 
in codes between 2011/12 and 2012/13. 
 
For example, the CHE version identifies nearly 8,000 HIV services and the toolkit only 7.  Further 
inspection shows that the HES provider spell number, a field used for quality checking but not 
service identification, is missing in all but 7 of these cases.  Thus the PSS toolkit identifies these 7 
cases. In contrast, PSS CHE version, which does not implement any of these quality checks, identifies 
nearly 8,000.  The missing provider spell number does trigger the allocation of a UZ01Z HRG in the 
grouping stage so we are unable to allocate a cost to these episodes. Consequently, the frequency of 
PSS HIV services in the analytical dataset is nil irrespective of whether the PSS CHE or PSS Toolkit is 
used. 
 
To further determine the extent to which the inherent PSS toolkit quality checks are responsible for 
ƚŚĞ ƌĞŵĂŝŶŝŶŐ  ‘ĞǆĐĞƐƐ ?difference between PSS CHE and the PSS toolkit, we took those FCEs for 
which the PSS CHE identified a PSS and the PSS toolkit version did not. For those records we changed 
the data items that are used for quality checking but not used in the identification of a service into 
values that would not trip the quality alarm.  These fields are:  diagnosis codes following the primary 
diagnosis, provider spell number and purchaser code number.  This accounts for approximately 85% 
of the additional PSS CHE identified codes.  
 
Given that the same issue may affect the primary diagnosis code which is a field checked for 
identification of services, the technical group agreed that the PSS CHE version mirrored the PSS 
toolkit sufficiently and that observed differences were attributed to quality check factors or to to the 
ICD update that was not applicable for 2011/12 data.  The conclusion was that the PSS CHE version 
was to be adopted as the means of identifying PSS services for the analysis. 
 
3. HIV specialisation. As discussed the CHE version identifies approximately 8,000 FCEs which 
qualify for the HIV 14Z service.  The toolkit identifies 7 such cases.  This is almost exclusively due 
to missing spell provider numbers in the HES record which the PSS toolkit uses as a quality 
check.  This data field plays no part in identification rules per se.  
 
Missing provider spell numbers also seem to be disproportionately high in these FCEs (i.e. they 
account for 10% of all missing provider spell numbers in the entire HES dataset).  In terms of the 
analysis dataset we find that the missing provider spell number always generates a UZ01Z HRG and 
so we have no HIV cases in our analytical dataset.  
 
As with PSS toolkit identification, the provider spell number does not have a crucial HRG 
identification role especially when dealing with FCEs.  As a missing provider spell number seems to 
be an artefact associated with HIV, possibly due to sensitivity/privacy issues, we could therefore 
ŝŵƉƵƚĞ  ‘ĐŽƌƌĞĐƚ ? ƉƌŽǀŝĚĞƌ ƐƉĞůů ŶƵŵďĞƌƐ ƚŽ ŐĞŶĞƌĂƚĞ ŶŽ -UZ01Z HRGs for the HIV cases and re-
introduce them into our dataset.  The technical working party decided against this option. 
 
4. The ICD10 update has caused a potential mismatch between the diagnosis codes contained in 
the Identification Rules and those in the 2011/12 HES dataset.  Fortunately the impact appears 
rather limited.  The following table shows the updates of ICD codes that appear in the rule sets 
and involves mostly 1:1 mappings.  
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code_description 
code (4th 
edition) 
map (to old code) N in diag_1 
  
 
 
Tuberculosis of ear A186 A186D 2 
Chagas' disease (chronic) with heart 
involvement 
B572 
(B572D + I412A) or 
(B572D + I981A) 
(1+0 [1 case in 
diag_2]) or (1+0) 
Echinococcus granulosus infection, 
unspecified 
B674 B674 or B711 0 or 0 
Angiostrongyliasis due to 
Parastrongylus cantonensis 
B832 B832 or B838 0 or 1 
Idiopathic acute pancreatitis K850 K85X 
30,242 
Biliary acute pancreatitis K851 K85X 
Alcohol-induced acute pancreatitis K852 K85X 
Drug-induced acute pancreatitis K853 K85X 
Other acute pancreatitis K858 K85X 
Acute pancreatitis, unspecified K859 K85X 
Necrotizing fasciitis M726 M725 166 
Severe acute respiratory syndrome 
[SARS], unspecified 
U049 J128 + B972 
159 +  0 (34 cases in 
diag2) 
  
The fourth column of this table lists the number of times these old ICD codes were found in diag_1 
(and in the case of the combination codes, diag_2 also).  As can be seen there seems little scope for 
much to change with the exception of the pancreatitis codes (K85X) and Necro fasciitis (M725). 
 
Fortunately the K85- changes all appear in one rule: NCBPS19Z A02 - Hepatology and Pancreatic.  
This makes for a relatively simple adaptation to accommodate the ICD changes: we simply add K85X 
as one of the triggering codes in the list of codes that that rule checks for.  Similarly for M726 it only 
appears in NCBPS18C Infectious Diseases Paeds B07 - Infectious Diseases and an analogous solution 
has been implemented. 
 
The technical working party agreed that this simple solution should be implemented for the analysis.  
As these ICD codes are checked in combination with other qualifying variables it has meant that a 
further 72 PSS services in NCBPS19Z and 2059 services in NCBPS18C have been identified. 
 
 
 
